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Abstract
We propose a general and formal statistical framework for the multiple tests of
associations between known fixed features of a genome and unknown parameters
of the distribution of variable features of this genome in a population of inter-
est. The known fixed gene-annotation profiles, corresponding to the fixed features
of the genome, may concern Gene Ontology (GO) annotation, pathway member-
ship, regulation by particular transcription factors, nucleotide sequences, or pro-
tein sequences. The unknown gene-parameter profiles, corresponding to the vari-
able features of the genome, may be, for example, regression coefficients relating
genome-wide transcript levels or DNA copy numbers to possibly censored bio-
logical and clinical outcomes and covariates. A generic question of great interest
in current genomic research, regarding the detection of associations between bio-
logical annotation metadata and genome-wide expression measures, may then be
translated into the multiple tests of hypotheses concerning association measures
between gene-annotation and gene-parameter profiles. A general and rigorous
formulation of the statistical inference question allows us to apply the multiple
testing methodology developed in Dudoit and van der Laan (2006) and related ar-
ticles, to control a broad class of Type I error rates, in testing problems involving
general data generating distributions (with arbitrary dependence structures among
variables), null hypotheses, and test statistics. Resampling-based single-step and
stepwise multiple testing procedures, that take into account the joint distribution
of the test statistics, are provided to control Type I error rates defined as tail prob-
abilities for arbitrary functions of the numbers of false positives and rejected hy-
potheses.
The proposed statistical and computational methods are illustrated using the acute
lymphoblastic leukemia (ALL) microarray dataset of Chiaretti et al. (2004), with
the aim of relating GO annotation to differential gene expression between B-cell
ALL with the BCR/ABL fusion and cytogenetically normal NEG B-cell ALL.
The sensitivity of the identified lists of GO terms to the choice of association
parameter between GO annotation and differential gene expression demonstrates
the importance of translating the biological question in terms of suitable gene-
annotation profiles, gene-parameter profiles, and association measures. In partic-
ular, the results show the limitations of binary gene-parameter profiles of differ-
ential expression indicators, which are still the norm for combined GO annotation
and microarray data analyses. Procedures based on such binary gene-parameter
profiles tend to be conservative and lack robustness with respect to the estimator
for the set of differentially expressed genes.
WWW companion: www.stat.berkeley.edu/∼sandrine/Docs/Papers/DFF06/DFF.html
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1 Introduction
1.1 Motivation
Experimental data, such as microarray gene expression measures, gain much
in relevance from their association with biological annotation metadata, i.e.,
data on data, such as, GenBank sequences, Gene Ontology terms, KEGG path-
ways, and PubMed abstracts. A challenging and fascinating area of research
for statisticians concerns the development of methods for relating experimental
data to the wealth of metadata available publicly on the WWW. This includes
accessing and pre-processing the data, making inference from these data, and
summarizing and interpreting the results.
In this context, an important class of statistical problems involves testing for
associations between known ﬁxed features of a genome and unknown parameters
of the distribution of variable features of this genome in a population of interest.
Here, features of a genome are said to be ﬁxed, if they remain constant among
population units. In contrast, variable features are allowed to diﬀer among
population units. Fixed features typically consist of gene annotation metadata,
that reﬂect current knowledge on gene properties, such as, nucleotide and protein
sequences, regulation, and function. Variable features often consist of gene
expression measures, that reﬂect cellular type and/or state under particular
conditions. The ﬁxed and variable features deﬁne, respectively, gene-annotation
proﬁles and gene-parameter proﬁles; the parameter of interest then corresponds
to measures of association between known gene-annotation proﬁles and unknown
gene-parameter proﬁles.
For instance, for the yeast Saccharomyces cerevisiae (in short, S. cerevisiae),
one may be interested in detecting associations between the vector of mean tran-
script (i.e., mRNA) levels for all (approximately 6,500) genes under heat-shock
conditions and Gene Ontology (GO) annotation for these genes. The reader is
referred to the Gene Ontology Consortium website (www.geneontology.org)
and to Section 4, below, for more information on gene ontologies, and to the
Saccharomyces Genome Database (SGD) website (www.yeastgenome.org), for
details on S. cerevisiae. In this example, the population of interest may consist
of all heat-shocked yeast cells from well-deﬁned cultures of a particular strain of
S. cerevisiae (e.g., strain S288C). For each of the three gene ontologies (BP, CC,
and MF, as described in Section 4.1), each gene is annotated with a ﬁxed set of
GO terms (i.e., this set is constant across population units for a given version of
the GO Database). Thus, for each GO term, one may deﬁne a gene-annotation
proﬁle as a known, ﬁxed binary vector indicating for each gene whether it is
annotated or not with the particular GO term. The transcript levels, however,
vary among population units and the gene-parameter proﬁle, i.e., the vector
of genome-wide mean transcript levels in the population of heat-shocked yeast
cells, is unknown and may be estimated, for example, from a microarray exper-
iment involving a sample of yeast cells from the population. The association
parameter of interest, between GO annotation and transcript levels, is then a
vector of association measures (e.g., two-sample t-statistics) between the known
3
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binary gene-annotation proﬁles and the unknown continuous gene-parameter
proﬁle.
Similar inference questions arise in many other contexts and involve a vari-
ety of deﬁnitions for the gene-annotation proﬁles, the gene-parameter proﬁles,
and the association parameters of interest. For example, in cancer microarray
studies, one may seek associations between GO gene-annotation proﬁles and
a gene-parameter proﬁle of regression coeﬃcients relating (censored) patient
survival data to genome-wide transcript levels or DNA copy numbers. Further-
more, gene-annotation proﬁles need not be binary or even polychotomous, and
may correspond to pathway membership, regulation by particular transcription
factors, nucleotide sequences, and protein sequences.
Note that, for the sake of illustration, we focus on gene-level features. How-
ever, our proposed methodology is generic and may be applied to other types of
features, such as those concerning gene isoforms and proteins. For instance, as
in alternative splicing microarray analysis, one may collect data at the ﬁner level
of gene isoforms, where one gene may have multiple isoforms (Blanchette et al.,
2005). In this context, isoform-parameter proﬁles may refer to the distribution
of isoform microarray expression measures in a well-deﬁned population, while
isoform-annotation proﬁles may consist of intron/exon counts/lengths/nucleotide
distributions. One may also consider protein-level features, where, for example,
protein-parameter proﬁles correspond to antibody microarray expression mea-
sures and protein-annotation proﬁles refer to protein function, domain struc-
ture, and post-translational modiﬁcation (e.g., from Swiss-Prot; www.expasy.
org/spro).
1.2 Contrast with other approaches
Existing approaches for tests of association with biological annotation meta-
data focus primarily on relating microarray gene expression measures and GO
annotation. Relevant articles and software packages include: FatiGO from
the BABELOMICS suite (Al-Shahrour et al. (2004, 2005); www.babelomics.org);
GOstat (Beissbarth and Speed (2004); gostat.wehi.edu.au); Ontologizer
(Grossmann et al. (2006); www.charite.de/ch/medgen/ontologizer); McCar-
roll et al. (2004); GSEA-P (Mootha et al. (2003), Subramanian et al. (2005);
www.broad.mit.edu/gsea/doc/doc_index.html); Tian et al. (2005). Methods
proposed thus far suﬀer from a number of limitations, related, to a large extent,
to the absence of a clear and precise statement of the statistical inference ques-
tion. As a result, the analyses often lack statistical rigor and tend to be ad hoc
and dataset-speciﬁc.
One of our main contributions is the systematic and precise translation of
a general class of biological questions into a corresponding class of multiple
hypothesis testing problems. A key step in this process is the proper deﬁni-
tion of the gene-annotation proﬁles, gene-parameter proﬁles, and association
parameters of interest. This general formulation then allows us to apply the
multiple testing methodology developed in Dudoit and van der Laan (2006) and
related articles (Birkner et al., 2005; Dudoit et al., 2004a,b; Keles¸ et al., 2004;
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van der Laan et al., 2004a,b, 2005; van der Laan and Hubbard, 2005; Pollard
et al., 2005a,b; Pollard and van der Laan, 2004; Rubin et al., 2005), to con-
trol a broad class of Type I error rates, deﬁned as generalized tail probabilities
(gTP), gTP (q, g) = Pr(g(Vn, Rn) > q), for arbitrary functions g(Vn, Rn) of the
numbers of false positives Vn and rejected hypotheses Rn.
We wish to emphasize the crucial and often ignored distinction between:
(i) the deﬁnition of a parameter of interest, measuring the association between
gene-annotation and gene-parameter proﬁles, i.e., the statistical formulation of
the biological question; (ii) making inferences, i.e., deriving estimators of and
testing hypotheses concerning this parameter, based on a sample drawn from
the population under consideration. Most methods proposed to date focus on
(ii), without providing a clear statement of the question being answered in (i),
that is, various estimation and testing approaches are proposed for an undeﬁned
parameter of interest.
Due to its general and rigorous statistical framework, our approach to mul-
tiple tests of association with biological annotation metadata diﬀers in a num-
ber of important ways from current approaches, such as those developed for
inference with Gene Ontology metadata and implemented in the software pack-
ages listed on the “Gene Ontology Tools” webpage (www.geneontology.org/
GO.tools.shtml).
1. General gene-annotation proﬁles. Existing approaches typically consider
binary gene-annotation proﬁles, e.g., vectors of indicators of GO term an-
notation. Our general deﬁnition of gene-annotation proﬁles allows con-
sideration of arbitrary qualitative and quantitative ﬁxed features of a
genome, e.g., membership of genes to any number of pathways or clusters,
intron/exon counts/lengths/nucleotide distributions, mean transcript lev-
els.
2. General gene-parameter proﬁles. Existing approaches typically consider
binary gene-parameter proﬁles, e.g., vectors of indicators of diﬀerential
expression. Our general deﬁnition of gene-parameter proﬁles allows con-
sideration of a much broader class of testing problems, concerning arbi-
trary qualitative and quantitative parameters, such as diﬀerences in mean
expression levels or regression coeﬃcients relating expression levels to clin-
ical outcomes.
3. Estimated gene-parameter proﬁles. Existing approaches typically assume
known gene-parameter proﬁles. For example, the list of diﬀerentially ex-
pressed genes from a microarray experiment is usually treated as known
and ﬁxed in subsequent analyses with GO, while in fact it corresponds to
an unknown and estimated parameter. Distinguishing between the deﬁni-
tion of a parameter and inference concerning this parameter, as in Section
3, provides a more rigorous and general formulation of the statistical ques-
tion.
4. General tests of association. Common approaches to tests of associa-
tion with GO annotation are typically limited to tests of independence in
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2 × 2 contingency tables (e.g., based on the hypergeometric distribution,
Fisher’s exact test). As in Table 2, rows correspond to gene annotation
with a given GO term (ﬁxed binary gene-annotation proﬁle) and columns
to an“interesting”gene property, such as diﬀerential expression (treated as
a ﬁxed binary gene-parameter proﬁle). The approach proposed in Section
3 allows consideration of a broader class of biological testing problems,
while properly accounting for the fact that gene-parameter proﬁles are
usually unknown and replaced by a random (i.e., data-driven) estimator.
1.3 Outline
This article proposes a general and formal statistical framework for multiple tests
of association with biological annotation metadata, using the multiple testing
methodology of Dudoit and van der Laan (2006) and related articles.
Section 2 provides an introduction to multiple hypothesis testing. Section
3 presents the proposed statistical framework for multiples tests of association
with biological annotation metadata and discusses in detail the main compo-
nents of the inference problem, namely, the gene-annotation proﬁles, the gene-
parameter proﬁles, and the association parameters. Multiple testing procedures
for tests of association between gene-annotation proﬁles and gene-parameter
proﬁles are outlined. Section 4 gives an overview of the Gene Ontology (GO)
and R software for analyzing GO annotation metadata (e.g., for assembling GO
gene-annotation proﬁles). The proposed statistical and computational meth-
ods are illustrated in Section 5, using the acute lymphoblastic leukemia (ALL)
microarray dataset of Chiaretti et al. (2004), with the aim of relating GO anno-
tation to diﬀerential gene expression between B-cell ALL with the BCR/ABL
fusion and cytogenetically normal NEG B-cell ALL. Finally, Section 6 summa-
rizes our ﬁndings and outlines ongoing work.
2 Overview of multiple hypothesis testing
This section introduces a general statistical framework for multiple hypothesis
testing and summarizes in turn the main ingredients of a multiple testing prob-
lem, including: the data generating distribution; the parameters of interest; the
null and alternative hypotheses; the test statistics; rejection regions (i.e., cut-
oﬀs) for the test statistics; Type I and Type II errors; Type I error rates and
power; the test statistics null distribution; multiple testing procedures; adjusted
p-values.
The reader is referred to our earlier articles and book for further detail on the
multiple testing methodology, its software implementation, and its application
to a variety of testing problems in biomedical and genomic research (Birkner
et al., 2005; Dudoit and van der Laan, 2006; Dudoit et al., 2004a,b; Keles¸ et al.,
2004; van der Laan et al., 2004a,b, 2005; van der Laan and Hubbard, 2005;
Pollard et al., 2005a,b; Pollard and van der Laan, 2004; Rubin et al., 2005).
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2.1 Null and alternative hypotheses
Hypothesis testing is concerned with using observed data to make decisions re-
garding properties of (i.e., hypotheses for) the unknown data generating distri-
bution.
Let Xn ≡ {Xi : 1, . . . , n} denote a random sample of n independent and iden-
tically distributed (i.i.d.) random variables from a data generating distribution
P , i.e., Xi
i.i.d.∼ P , i = 1, . . . , n. Suppose that the data generating distribution
P is an element of a particular statistical model M, i.e., a set of possibly non-
parametric distributions, P ∈ M. Let Pn denote the corresponding empirical
distribution, which places probability 1/n on each realization of X.
In order to cover a broad class of testing problems, specify M pairs of null
and alternative hypotheses in terms of a collection of M submodels,M(m) ⊆M,
m = 1, . . . ,M , for the data generating distribution P . The M null hypotheses
and corresponding alternative hypotheses are deﬁned as
H0(m) ≡ I(P ∈M(m)) and H1(m) ≡ I(P /∈M(m)), (1)
respectively. Here, I(·) is the indicator function, equaling one if the condition in
parentheses is true and zero otherwise.
In many testing problems, the submodels concern parameters, i.e., functions
Ψ(P ) = ψ = (ψ(m) : m = 1, . . . ,M) of the data generating distribution P , and
each null hypothesis may refer to a single parameter, ψ(m) = Ψ(P )(m) ∈ IR.
This general submodel representation covers tests of means, quantiles, cor-
relation coeﬃcients, and regression coeﬃcients in linear and non-linear models
(e.g., logistic, survival, time-series, and dose-response models).
Let H0 = H0(P ) ≡ {m : H0(m) = 1} and H1 = H1(P ) ≡ Hc0(P ) = {m :
H1(m) = 1} denote, respectively, the sets of h0 ≡ |H0| true null hypotheses and
h1 ≡ |H1| = M − h0 false null hypotheses, i.e., true positives.
2.2 Test statistics and rejection regions
The goal of a multiple testing procedure (MTP) is to accurately estimate, i.e.,
reject, the set H1 of true positives, while probabilistically controlling false posi-
tives.
The decisions to reject or not the null hypotheses are based on an M–
vector of test statistics, Tn = (Tn(m) : m = 1, . . . ,M), that are functions
Tn(m) = T (m;Xn) of the data Xn. A broad class of testing problems may be
addressed using diﬀerence statistics and t-statistics (Equations (20) and (21),
respectively). Denote the typically unknown (ﬁnite sample) joint distribution of
the test statistics Tn by Qn = Qn(P ).
A MTP provides rejection regions Cn(m), i.e., sets of values for each test
statistic Tn(m) that lead to the decision to reject the corresponding null hy-
pothesis H0(m), m = 1, . . . ,M . In other words, a MTP produces a random
(i.e., data-driven) subset Rn of rejected hypotheses that estimates the set H1
of true positives,
Rn ≡ {m : Tn(m) ∈ Cn(m)} = {m : H0(m) is rejected}. (2)
7
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2.3 Errors in multiple hypothesis testing
2.3.1 Type I and Type II errors
In any testing situation, two types of errors can be committed: a false positive,
or Type I error, is committed by rejecting a true null hypothesis (Rn∩H0), and
a false negative, or Type II error, is committed when the test procedure fails to
reject a false null hypothesis (i.e., a true positive) (Rcn ∩H1).
The main decisions and errors in a multiple testing problem are summarized
in Table 1, below, where the numbers of rejected hypotheses, Type I errors, and
Type II errors are deﬁned as
Rn ≡ |Rn| =
M∑
m=1
I(Tn(m) ∈ Cn(m)), (3)
Vn ≡ |Rn ∩H0| =
∑
m∈H0
I(Tn(m) ∈ Cn(m)),
and Un ≡ |Rcn ∩H1| =
∑
m∈H1
I(Tn(m) /∈ Cn(m)),
respectively. Note that both Un and Vn depend on the unknown data generating
distribution P through the unknown set of true null hypotheses H0 = H0(P ).
Therefore, the numbers h0 = |H0| and h1 = |H1| = M − h0 of true and false
null hypotheses are unknown parameters, the number of rejected hypotheses Rn
is an observable random variable, and the entries in the body of the table, Un,
h1 − Un, Vn, and h0 − Vn, are unobservable random variables (that depend on
the unknown data generating distribution P through H0(P )).
Ideally, one would like to simultaneously minimize both the number of Type
I errors and the number of Type II errors. Unfortunately, this is not feasible
and one seeks a trade-oﬀ between the two types of errors. A standard approach
is to specify an acceptable level α for a suitably deﬁned Type I error rate and
derive testing procedures, i.e., rejection regions, that aim to minimize a Type II
error rate, i.e., maximize power, within the class of tests with Type I error rate
at most α.
2.3.2 Type I error rates and power
When testing multiple hypotheses, there are many possible deﬁnitions for the
Type I error rate and power of a test procedure. Accordingly, we deﬁne a Type
I error rate as an arbitrary parameter θn = θ(FVn,Rn) of the joint distribution
FVn,Rn of the numbers of Type I errors Vn = |Rn∩H0| and rejected hypotheses
Rn. Likewise, power may be deﬁned as a parameter ϑn = ϑ(FUn,Rn) of the
joint distribution FUn,Rn of the numbers of Type II errors Un = |Rcn ∩H1| and
rejected hypotheses Rn.
Type I error rates of particular interest are generalized tail probability (gTP)
error rates,
gTP (q, g) ≡ Pr(g(Vn, Rn) > q), (4)
8
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and generalized expected value (gEV) error rates,
gEV (g) ≡ E[g(Vn, Rn)], (5)
for arbitrary functions g(Vn, Rn) of the numbers of false positives Vn and rejected
hypotheses Rn and user-supplied bounds q.
Generalized tail probability error rates include as special cases the following
commonly-used Type I error rates.
• The generalized family-wise error rate (gFWER), corresponding to g(v, r) =
v and q ∈ {0, . . . , (h0 − 1)}, is the probability of at least (q + 1) Type I
errors,
gFWER(q) ≡ Pr(Vn > q) = 1− FVn(q). (6)
When q = 0, the gFWER reduces to the usual family-wise error rate
(FWER), controlled by the classical Bonferroni procedure.
• The tail probability for the proportion of false positives (TPPFP) among
the rejected hypotheses, corresponding to g(v, r) = v/r and q ∈ (0, 1), is
deﬁned as
TPPFP (q) ≡ Pr
(
Vn
Rn
> q
)
= 1− FVn/Rn(q), (7)
with the convention that Vn/Rn ≡ 0 if Rn = 0.
The generalized expected value error rate for g = v/r corresponds to the false
discovery rate (FDR), i.e., the expected proportion of false positives among the
rejected hypotheses,
FDR ≡ E
[
Vn
Rn
]
=
∫
qdFVn/Rn(q), (8)
again with the convention that Vn/Rn ≡ 0 if Rn = 0.
2.4 Test statistics null distribution
As discussed in Section 3.4, below, a key feature of our proposed multiple testing
procedures is the test statistics null distribution used to obtain rejection regions
(i.e., cut-oﬀs) for the test statistics, conﬁdence regions for the parameters of
interest, and adjusted p-values. Indeed, whether testing single or multiple hy-
potheses, one needs the (joint) distribution of the test statistics in order to derive
a procedure that probabilistically controls Type I errors. In practice, however,
the true distribution Qn(P ) of the test statistics is unknown and replaced by
a null distribution Q0. The choice of a suitable null distribution is crucial, in
order to ensure that (ﬁnite sample or asymptotic) control of the Type I error
rate under the assumed null distribution does indeed provide the desired control
under the true distribution.
9
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2.5 Multiple testing procedures
Having identiﬁed a suitable test statistics null distribution Q0 (or estimator
thereof, Q0n), there remains the main task of specifying rejection regions Cn(m)
for each null hypothesis H0(m). As detailed in Dudoit and van der Laan (2006)
and as summarized in Section 3.4, below, we have developed resampling-based
single-step and stepwise multiple testing procedures for controlling a broad class
of Type I error rates, in testing problems involving general data generating
distributions (with arbitrary dependence structures among variables), null hy-
potheses (deﬁned in terms of submodels for the data generating distribution),
and test statistics (e.g., t-statistics, χ2-statistics, F -statistics). Procedures that
take into account the joint distribution of the test statistics are provided to
control Type I error rates deﬁned as tail probabilities and expected values for
arbitrary functions g(Vn, Rn) of the numbers of false positives Vn and rejected
hypotheses Rn.
2.6 Adjusted p-values
As in the case of single hypothesis testing, one can report the results of a multiple
testing procedure in terms of the following quantities: rejection regions for the
test statistics, conﬁdence regions for the parameters of interest, and adjusted
p-values.
Adjusted p-values, for the test of multiple hypotheses, are deﬁned as straight-
forward extensions of unadjusted p-values, for the test of individual hypotheses.
Consider any multiple testing procedure Rn(α) = R(Tn, Q0, α), with rejection
regions Cn(m;α) = C(m;Tn, Q0, α). Then, the adjusted p-value for null hypoth-
esis H0(m) is deﬁned as
P˜0n(m) ≡ inf {α ∈ [0, 1] : Reject H0(m) at nominal MTP level α} (9)
= inf {α ∈ [0, 1] : m ∈ Rn(α)}
= inf {α ∈ [0, 1] : Tn(m) ∈ Cn(m;α)} , m = 1, . . . ,M.
That is, P˜0n(m) is the smallest nominal Type I error level (e.g., gFWER,
TPPFP, or FDR) of the multiple hypothesis testing procedure at which one would
reject H0(m), given Tn.
For example, the adjusted p-values for the classical FWER-controlling marginal
Bonferroni procedure are P˜0n(m) = min(MP0n(m), 1). Adjusted p-values for
FWER-controlling joint single-step common-cut-oﬀ maxT Procedure 1 are given
in Equation (25).
As in single hypothesis tests, the smaller the adjusted p-value P˜0n(m), the
stronger the evidence against the corresponding null hypothesis H0(m). Specif-
ically, for a multiple test at nominal Type I error level α, one has two equivalent
representations for the set of rejected hypotheses, in terms of rejection regions
for the test statistics and in terms of adjusted p-values,
Rn(α) = {m : Tn(m) ∈ Cn(m;α)} = {m : P˜0n(m) ≤ α}. (10)
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Reporting the results of a MTP in terms of adjusted p-values, as opposed to
only rejection or not of the null hypotheses, oﬀers several advantages.
• Adjusted p-values can be deﬁned for any Type I error rate (e.g., gFWER,
TPPFP, or FDR).
• They reﬂect the strength of the evidence against each null hypothesis in
terms of the Type I error rate for the entire MTP.
• They are ﬂexible summaries of a MTP, in the sense that results are sup-
plied for all Type I error levels α, i.e., the level α need not be chosen ahead
of time.
• They provide convenient benchmarks to compare diﬀerent MTPs, whereby
smaller adjusted p-values indicate a less conservative procedure.
• Plots of sorted adjusted p-values allow investigators to examine sets of re-
jected hypotheses associated with various Type I error rates (e.g., gFWER,
TPPFP, or FDR) and nominal levels α. Such plots provide tools to de-
cide on an appropriate combination of number of rejected hypotheses and
tolerable false positive rate for a particular experiment and available re-
sources.
3 Statistical framework for multiple tests of as-
sociation with biological annotation metadata
Sections 3.1 – 3.3 introduce the main components of our approach to multiple
tests of association with biological annotation metadata, namely: the gene-
annotation proﬁles A, the gene-parameter proﬁles λ, and the association mea-
sures ψ = ρ(A, λ) between gene-annotation and gene-parameter proﬁles. We
stress that the choice of a suitable association parameter ψ is perhaps the most
important and hardest aspect of the inference problem, as this parameter rep-
resents the statistical translation of the biological question of interest. Once
the association parameter ψ is appropriately and precisely deﬁned, one can rely
on a variety of statistical methods to estimate and test hypotheses concerning
this parameter. Section 3.4 describes how the multiple testing methodology of
Dudoit and van der Laan (2006) and related articles may be used to detect
associations between gene-annotation and gene-parameter proﬁles.
Note that, for the sake of illustration, we focus on gene-level features. How-
ever, as mentioned in Section 1.1, the methodology is generic and may be applied
to other types of features, such as those concerning gene isoforms and proteins.
3.1 Gene-annotation proﬁles
Gene-annotation proﬁles refer to features of a genome that are assumed to be
known and constant among units in a population of interest. Such features
typically consist of gene annotation metadata, that reﬂect current knowledge
11
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on gene properties, such as, nucleotide and protein sequences, regulation, and
function.
Speciﬁcally, let A = (A(g,m) : g = 1, . . . , G; m = 1, . . . ,M) denote a G ×
M gene-annotation matrix, providing data on M features for G genes in an
organism of interest. Thus, row A(g, ·) ≡ (A(g,m) : m = 1, . . . ,M) denotes
an M–dimensional gene-speciﬁc feature vector for the gth gene, g = 1, . . . , G,
and column A(·,m) ≡ (A(g,m) : g = 1, . . . , G) denotes a G–dimensional gene-
annotation proﬁle for the mth feature, m = 1, . . . ,M .
In many applications, the element A(g,m) is a binary indicator, coding
the YES/NO answer to the mth question, among a collection of M ques-
tions, one may ask about gene g. For example, A(g,m) could indicate whether
gene g is annotated with a particular GO term m, among M terms in one of
the three ontologies (BP, CC, or MF), i.e., whether gene g is an element of
the node corresponding to the mth term in the GO directed acyclic graph
(DAG). Other gene-annotation proﬁles of interest may refer to intron/exon
counts/lengths/nucleotide distributions, gene pathway membership (e.g., from
the Kyoto Encyclopedia of Genes and Genomes, KEGG; www.genome.ad.jp/
kegg), or gene regulation by particular transcription factors. Regarding tran-
scription regulation, one could use data from the Transcription Factor DataBase
(TRANSFAC; www.gene-regulation.com) to generate gene-annotation pro-
ﬁles as follows. For a given transcription factor binding motif, a binary gene-
annotation proﬁle could consist of indicators for the presence or absence of the
motif in the upstream control region of each gene. A continuous gene-annotation
proﬁle could be based on the position weight matrix of the binding motif.
Note that the aforementioned features are only ﬁxed in time for a given
version/release of the corresponding database(s), i.e., such biological data are
constantly evolving as our knowledge of the roles of genes and proteins is accu-
mulating and changing. The dynamic nature of biological annotation metadata
is an important issue in terms of software design (Section 4.2; Gentleman et al.
(2005)). Note also that the gene-annotation proﬁles are not restricted to be
binary or even polychotomous and, in particular, could be continuous gene-
parameter proﬁles, suitably estimated from previous studies.
The main point, regarding the formulation of the statistical inference ques-
tion, is that gene-annotation proﬁles are known and constant among population
units.
3.2 Gene-parameter proﬁles
Gene-parameter proﬁles are generally unknown and concern the distribution
of variable features of a genome in a well-deﬁned population. Gene-speciﬁc
variables of interest reﬂect cellular type and/or state under particular conditions
and include microarray measures of transcript levels and comparative genomic
hybridization (CGH) measures of DNA copy numbers.
Speciﬁcally, let X be a J–dimensional random vector, containing G gene-
speciﬁc random variables (X(g) : g = 1, . . . , G). In addition to the G gene-
speciﬁc variables, X may include various biological and clinical covariates (e.g.,
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age, sex, treatment, timepoint) and outcomes (e.g., survival time, response to
treatment, tumor class). Let P denote the data generating distribution for the
random J–vector X and suppose that P belongs to a (possibly non-parametric)
model M.
Let the parameter mapping Λ : M → IRG deﬁne a G–dimensional gene-
parameter proﬁle, Λ(P ) = λ = (λ(g) : g = 1, . . . , G), where each λ(g) =
Λ(P )(g) ∈ IR is a gene-speciﬁc real-valued parameter. For example, λ(g) could
be the mean expression measure E[X(g)] of gene g or a regression coeﬃcient in
a model relating an outcome component of X to the expression measure X(g)
of gene g, g = 1, . . . , G.
While gene-annotation proﬁles are known and ﬁxed, gene-parameter pro-
ﬁles are typically unknown and need to be estimated, e.g., from a microarray
experiment involving a sample of population units. The sample is assumed to
consist of n independent and identically distributed (i.i.d.) copies of X ∼ P ,
Xn = {Xi : 1, . . . , n}, corresponding to n randomly sampled population units.
3.3 Association measures for gene-annotation and gene-
parameter proﬁles
Let the parameter mapping Ψ : M→ IRM specify an M–dimensional associa-
tion parameter vector,
Ψ(P ) = ψ = (ψ(m) : m = 1, . . . ,M) ≡ ρ(A,Λ(P )), (11)
deﬁned in terms of an association measure ρ : IRG×M ×IRG → IRM , known ﬁxed
gene-annotation proﬁles A, and an unknown gene-parameter proﬁle λ = Λ(P ).
The choice of a suitable association parameter is subject matter-dependent
and requires careful consideration. For instance, for Gene Ontology annotation,
it is desirable that the association parameter reﬂect the structure of the GO di-
rected acyclic graph (Section 4.1). In principle, the dimension of the association
parameter vector ψ could diﬀer from the number M of features under consid-
eration. In addition, one could accommodate several gene-parameter proﬁles
λ.
The various quantities in the inference problem are summarized in Figure 1;
examples of association parameters are given next and in Section 5.
3.3.1 Univariate association measures
In the simplest case, one could deﬁne the M association parameters univariately,
i.e., deﬁne ψ(m) based only on the mth gene-annotation proﬁle A(·,m), m =
1, . . . ,M . Speciﬁcally, for the mth feature, let
Ψ(P )(m) = ψ(m) ≡ ρm(A(·,m),Λ(P )), (12)
where ρm : IRG × IRG → IR provides a measure of association (e.g., correla-
tion coeﬃcient) between the G–dimensional gene-annotation proﬁle A(·,m) and
gene-parameter proﬁle λ = Λ(P ). In many situations, the same association
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measure ρm may be used for each of the M features.
Continuous gene-annotation proﬁles and continuous gene-parameter proﬁles.
For continuous gene-annotation and gene-parameter proﬁles, one may use as
association measure the Pearson correlation coeﬃcient between two G–vectors.
That is,
ψ(m) =
∑G
g=1(A(g,m)− A¯(m))(λ(g)− λ¯)√∑G
g=1(A(g,m)− A¯(m))2
√∑G
g=1(λ(g)− λ¯)2
, (13)
where A¯(m) ≡ ∑g A(g,m)/G and λ¯ ≡ ∑g λ(g)/G denote, respectively, the
averages of the G components of the gene-annotation proﬁle A(·,m) and gene-
parameter proﬁle λ.
Binary gene-annotation proﬁles and binary gene-parameter proﬁles. For binary
gene-annotation and gene-parameter proﬁles, one may build 2× 2 contingency
Table 2 and use as association measure the χ2-statistic (or corresponding p-
value) for the test of independence of rows and columns. That is,
ψ(m) =
G(g00(m)g11(m)− g01(m)g10(m))2
(g00(m) + g01(m))(g00(m) + g10(m))(g11(m) + g01(m))(g11(m) + g10(m))
,
(14)
where gkk′(m) ≡
∑
g I(A(g,m) = k)I(λ(g) = k
′), k, k′ ∈ {0, 1}. Note that in
this context the χ2-statistic ψ(m) is a parameter, i.e., it is a function of the
data generating distribution P , via the gene-parameter proﬁle λ = Λ(P ), and
is unknown and constant among population units.
Binary gene-annotation proﬁles. For binary gene-annotation proﬁles, one may
consider association parameter vectors of the form
ψ = Aλ. (15)
That is, the association parameter for the mth feature is the sum,
ψ(m) =
G∑
g=1
A(g,m)λ(g) =
G∑
g=1
I(A(g,m) = 1)λ(g),
of the parameters λ(g) for genes g that have the property of interest, i.e., such
that A(g,m) = 1. Such an association parameter is considered by Tian et al.
(2005), to relate continuous microarray diﬀerential expression gene-parameter
proﬁles to binary pathway gene-annotation proﬁles. The following standardized
association parameters (corresponding to association measures based on two-
sample t-statistics) may also be considered,
ψ(m) =
λ¯1(m)− λ¯0(m)√
v[λ]1(m)
A1(m)
+ v[λ]0(m)A0(m)
, (16)
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where, for the mth feature, Ak(m) ≡
∑
g I(A(g,m) = k), λ¯k(m) ≡
∑
g I(A(g,m) =
k)λ(g)/Ak(m), and v[λ]k(m) ≡
∑
g I(A(g,m) = k)(λ(g) − λ¯k(m))2/Ak(m) de-
note, respectively, the numbers, averages, and variances of annotated (k = 1)
and unannotated (k = 0) gene-parameters λ(g).
In commonly-encountered combined GO annotation and microarray data
analyses, a binary gene-parameter proﬁle could indicate whether genes are diﬀer-
entially expressed or not in two populations of cells, a continuous gene-parameter
proﬁle could consist of coeﬃcients for the regression of a (censored) clinical out-
come on gene expression measures, and binary gene-annotation proﬁles could
denote whether genes are annotated or not with particular GO terms (Section
5; Al-Shahrour et al. (2004, 2005); Beissbarth and Speed (2004); Grossmann
et al. (2006)).
3.3.2 Multivariate association measures
More generally, the mth association parameter could be based on the entire
gene-annotation matrix A or a subset of columns thereof, that is, Ψ(P )(m) =
ψ(m) ≡ ρm(A,Λ(P )), for an association measure ρm : IRG×M × IRG → IR.
Association parameters of interest include: linear combinations of association
parameters for several features, partial correlation coeﬃcients, χ2-statistics for
higher-dimensional contingency tables (e.g., with one dimension corresponding
to a gene-parameter proﬁle λ and other dimensions to several gene-annotation
proﬁles A(·,m)), (contrasts of) regression coeﬃcients of a gene-parameter proﬁle
λ on several gene-annotation proﬁles A(·,m).
In the case of Gene Ontology annotation, the association parameter ψ should
preferably reﬂect the structure of the GO directed acyclic graph, by taking into
account, for instance, annotation information for ancestor (i.e., less speciﬁc) or
oﬀspring (i.e., more speciﬁc) terms (Section 4.1). Speciﬁcally, let P(m) denote
the set of (immediate) parents of a term m. As the genes annotated by the
child term m are subsets of the genes annotated by the parent terms P(m),
then A(g,m) = 1 implies A(g, p) = 1 for p ∈ P(m).
Following the causal inference literature (van der Laan, 2006; van der Laan
and Robins, 2003), an association parameter of interest for GO term m is the
marginal causal eﬀect parameter, deﬁned as
ψ(m) = E[E[λ|A(·,m) = 1, A(·,P(m))]]− E[E[λ|A(·,m) = 0, A(·,P(m))]],
(17)
where A(·,P(m)) denotes the submatrix of gene-annotation proﬁles for parent
terms P(m) and the expected values are deﬁned with respect to the empirical
distribution of {(A(g,m), A(g,P(m)), λ(g)) : g = 1, . . . , G}.
In the special case of binary gene-parameter proﬁles (for diﬀerential expres-
sion), the so-called parent-child method of Grossmann et al. (2006) takes into
account the structure of the GO DAG by testing for associations between gene-
annotation and gene-parameter proﬁles using hypergeometric p-values computed
conditionally on the annotation status of parent terms.
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One could also consider Boolean combinations of annotation indicators for
multiple features, that is, a transformed gene-annotation matrix whose columns
are Boolean combinations of the columns of the original gene-annotation matrix.
Such an approach would be particularly relevant in the context of transcription
regulation, where individual features correspond to single transcription factor
binding motifs and Boolean combinations to binding modules for multiple tran-
scription factors.
3.4 Multiple hypothesis testing
3.4.1 Null and alternative hypotheses
Certain biological annotation metadata analyses may involve the two-sided tests
of the M null hypotheses of no association between the gene-annotation proﬁles
A(·,m) and a gene-parameter proﬁle λ, i.e., tests of
H0(m) ≡ I(ψ(m) = ψ0(m)) vs. H1(m) ≡ I(ψ(m) = ψ0(m)). (18)
Other analyses may call for the one-sided tests of
H0(m) ≡ I(ψ(m) ≤ ψ0(m)) vs. H1(m) ≡ I(ψ(m) > ψ0(m)). (19)
The M–vector ψ0 = (ψ0(m) : m = 1, . . . ,M), of null values for the asso-
ciation parameter ψ, is determined by the biological question. For example, if
ψ(m) = ρm(A(·,m), λ) is the Pearson correlation coeﬃcient between the gene-
annotation proﬁle A(·,m) and the gene-parameter proﬁle λ, then one may set
ψ0(m) = 0.
Note that in many situations, the same association measure ρm is used for
each of the M features and one only has a single, common null value ψ0(m).
3.4.2 Test statistics
As in Chapter 1 of Dudoit and van der Laan (2006), consider the general situa-
tion where, given a random sample Xn from the data generating distribution P ,
one has an asymptotically linear estimator ψn = Ψˆ(Pn) of the association param-
eter vector ψ = Ψ(P ), with M–dimensional vector inﬂuence curve IC(X | P ).
Let Σˆ(Pn) = σn = (σn(m,m′) : m,m′ = 1, . . . ,M) denote a consistent estima-
tor of the covariance matrix Σ(P ) = σ = (σ(m,m′) : m,m′ = 1, . . . ,M) of the
vector inﬂuence curve IC(X | P ). For example, σn could be a bootstrap-based
estimator of the covariance matrix σ or could be computed from an estimator
ICn(X) of the inﬂuence curve IC(X | P ).
Each null hypothesis H0(m) may then be tested using a (unstandardized)
diﬀerence statistic,
Tn(m) ≡
√
n (ψn(m)− ψ0(m)) , (20)
or a (standardized) t-statistic,
Tn(m) ≡
√
n
ψn(m)− ψ0(m)√
σn(m,m)
. (21)
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Let Qn = Qn(P ) denote the typically unknown (ﬁnite sample) joint distribution
of the M–vector of test statistics Tn = (Tn(m) : m = 1, . . . ,M), under the data
generating distribution P .
A broad range of association parameters ψ and corresponding estimators ψn
satisfy the above conditions. In particular, suppose λn = Λˆ(Pn) is an asymp-
totically linear estimator of the gene-parameter proﬁle λ = Λ(P ), based on a
random sample Xn from P . Let ψn ≡ ρ(A, λn) denote the corresponding resub-
stitution, or plug-in, estimator of the association parameter vector ψ = ρ(A, λ).
Then, if the function ρ(A, λ) is diﬀerentiable with respect to λ, the resubstitu-
tion estimator ψn is also asymptotically linear. One can therefore handle tests
where the gene-parameter proﬁles λ are (functions of) means, variances, correla-
tion coeﬃcients, and regression coeﬃcients, and where the association measures
ρ are correlation coeﬃcients, two-sample t-statistics, and χ2-statistics. Exam-
ples are provided in Section 5, in the context of tests of association between
diﬀerential gene expression in ALL and GO annotation.
Certain testing problems may call for other test statistics Tn, such as F -
statistics, χ2-statistics, and likelihood ratio statistics.
3.4.3 Test statistics null distribution
As detailed in Chapter 2 of Dudoit and van der Laan (2006), a key feature of
our proposed multiple testing procedures is the test statistics null distribution
(rather than data generating null distribution) used to obtain rejection regions
(i.e., cut-oﬀs) for the test statistics, conﬁdence regions for the parameters of
interest, and adjusted p-values. In practice, the true distribution Qn(P ) of the
test statistics Tn is unknown and replaced by a null distribution Q0. The choice
of a suitable null distribution is crucial, in order to ensure that (ﬁnite sample or
asymptotic) control of the Type I error rate under the assumed null distribution
does indeed provide the desired control under the true distribution. This issue
is particularly relevant for large-scale testing problems, such as those involving
gene annotation metadata, which concern high-dimensional multivariate distri-
butions, with complex and unknown dependence structures among variables.
Chapter 2 of Dudoit and van der Laan (2006) provides a general charac-
terization for a proper test statistics null distribution, in terms of null dom-
ination conditions for the joint distribution of the H0–speciﬁc test statistics
(Tn(m) : m ∈ H0). This general characterization leads to the explicit proposal
of two test statistics null distributions Q0 = Q0(P ): the asymptotic distribution
of the vector of null value shifted and scaled test statistics and the asymptotic
distribution of the vector of null quantile-transformed test statistics.
Speciﬁcally, the original null distribution of Dudoit et al. (2004b), van der
Laan et al. (2004b), and Pollard and van der Laan (2004) is deﬁned as the
asymptotic distribution of the M–vector Zn of null value shifted and scaled test
statistics,
Zn(m) ≡
√
min
(
1,
τ0(m)
V ar[Tn(m)]
)
(Tn(m)− E[Tn(m)]) + λ0(m), (22)
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where λ0(m) and τ0(m) are, respectively, user-supplied upper bounds for the
means and variances of the H0–speciﬁc test statistics. In this construction, the
location null values λ0(m) are chosen such that the joint distribution of (Zn(m) :
m ∈ H0) is asymptotically stochastically greater than that of (Tn(m) : m ∈ H0).
The scale null values τ0(m) are chosen to prevent a degenerate limit for the
false null hypotheses (m ∈ H1); an important issue for power considerations.
For a broad class of testing problems, such as the test of single-parameter null
hypotheses using t-statistics (Equation (21)), the null values are λ0(m) = 0
and τ0(m) = 1 and the null distribution is an M–variate Gaussian distribution,
with mean vector zero and covariance matrix equal to the correlation matrix
of the vector inﬂuence curve. That is, Q0 = N(0, σ∗), where σ∗ = Σ∗(P ) ≡
Cor[IC(X|P )]. For testing the equality of K population mean vectors using
F -statistics, the null values are λ0(m) = 1 and τ0(m) = 2/(K − 1), under the
assumption of equal variances in the diﬀerent populations.
The second and most recent proposal of van der Laan and Hubbard (2005)
is deﬁned as the asymptotic distribution of the M–vector Zn of null quantile-
transformed test statistics,
Zn(m) ≡ Q˙−10,mQn,m(Tn(m)), (23)
where Q˙0,m are user-supplied marginal test statistics null distributions that sat-
isfy the marginal null domination condition lim infn Q˙−10,mQn,m(z) ≥ z. This
latest proposal has the advantage that the marginal test statistics null distribu-
tions may be set to the optimal, i.e., most powerful, null distributions one would
use in single hypothesis testing (e.g., permutation null distributions, Gaussian
or other parametric null distributions).
In practice, the test statistics null distribution Q0 = Q0(P ) is unknown,
as it depends on the unknown data generating distribution P . Resampling
procedures are provided to conveniently obtain consistent estimators of the null
distribution and the corresponding test statistic cut-oﬀs, parameter conﬁdence
regions, and adjusted p-values.
We stress the generality of the aforementioned test statistics null distribu-
tions: Type I error control does not rely on restrictive assumptions such as
subset pivotality and holds for general data generating distributions (with arbi-
trary dependence structures among variables), null hypotheses (deﬁned in terms
of submodels for the data generating distribution), and test statistics (e.g., t-
statistics, χ2-statistics, F -statistics).
3.4.4 Multiple testing procedures
Having identiﬁed a suitable test statistics null distribution Q0 (or estimator
thereof, Q0n), there remains the main task of specifying rejection regions (i.e.,
cut-oﬀs) for the test statistics, conﬁdence regions for the parameters of in-
terest, and adjusted p-values. One can apply the multiple testing method-
ology developed in Dudoit and van der Laan (2006) and related articles to
control a broad class of Type I error rates, deﬁned as generalized tail prob-
abilities, gTP (q, g) = Pr(g(Vn, Rn) > q), and generalized expected values,
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gEV (g) = E[g(Vn, Rn)], for arbitrary functions g(Vn, Rn) of the numbers of
false positives Vn and rejected hypotheses Rn.
An overview of available MTPs is provided in Chapter 3 of Dudoit and
van der Laan (2006). Core methodological Chapters 4 – 8 discuss the following
main approaches for deriving rejection regions.
Chapter 4. Single-step common-cut-oﬀ and common-quantile procedures for
controlling general Type I error rates θ(FVn), deﬁned as arbitrary param-
eters of the distribution of the number of Type I errors Vn (Dudoit et al.,
2004b; Pollard and van der Laan, 2004). Error rates of the form θ(FVn)
include the generalized family-wise error rate, gFWER(q) = 1−FVn(q) =
Pr(Vn > q).
Chapter 5. Step-down common-cut-oﬀ (maxT) and common-quantile (minP)
procedures for controlling the family-wise error rate, FWER = gFWER(0) =
1− FVn(0) = Pr(Vn > 0) (van der Laan et al., 2004b).
Chapter 6. Augmentation multiple testing procedures (AMTP) for controlling
generalized tail probability error rates, gTP (q, g) = Pr(g(Vn, Rn) > q), for
arbitrary functions g(Vn, Rn) of the numbers of false positives Vn and
rejected hypotheses Rn, based on an initial gFWER-controlling procedure
(Dudoit et al., 2004a; van der Laan et al., 2004a). Error rates treated in
detail include the gFWER, with g(v, r) = v, and TPPFP, with g(v, r) =
v/r.
Chapter 7. Resampling-based empirical Bayes procedures for controlling gen-
eralized tail probability error rates. The special case of TPPFP control is
discussed in detail in van der Laan et al. (2005).
These multiple testing procedures are implemented in the Bioconductor R
package multtest (Pollard et al. (2005b); www.bioconductor.org).
3.4.5 FWER-controlling single-step common-cut-oﬀ maxT procedure
For the purpose of illustration, we focus on control of the family-wise error rate,
using the single-step maxT procedure, a common-cut-oﬀ procedure exploiting
the joint distribution of the test statistics. We rely on the bootstrap to yield
a consistent estimator Q0n of the null value shifted and scaled test statistics
null distribution Q0 and corresponding single-step maxT cut-oﬀs and adjusted
p-values. The method is summarized below for convenience; details are given in
Chapter 4 of Dudoit and van der Laan (2006) and in Dudoit et al. (2004b).
Procedure 1 [Single-step common-cut-oﬀ maxT procedure] Given an
M–variate test statistics null distribution Q0, the single-step common-cut-oﬀ
maxT procedure is based on the distribution of the maximum test statistic
maxm Z(m), for a random M–vector Z = (Z(m) : m = 1, . . . ,M) ∼ Q0. For
controlling the FWER at nominal level α ∈ [0, 1], the common cut-oﬀ c(Q0, α)
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is deﬁned as the (1− α)–quantile of the distribution of maxm Z(m), that is,
c(Q0, α) ≡ inf
{
z : PrQ0
(
max
m
Z(m) ≤ z
)
≥ (1− α)
}
. (24)
The adjusted p-value p˜0n(m) for null hypothesis H0(m) is the probability, under
Q0, that maxm Z(m) exceeds the corresponding observed test statistic tn(m),
that is,
p˜0n(m) = PrQ0
(
max
m
Z(m) ≥ tn(m)
)
, m = 1, . . . ,M. (25)
Procedure 2 [Bootstrap-based single-step common-cut-oﬀ maxT
procedure]
1. Given B (non-parametric or model-based) bootstrap samples of the data
Xn, obtain an M × B matrix of test statistics, TBn =
(
TBn (m, b)
)
, with
rows corresponding to the M null hypotheses and columns to the B boot-
strap samples.
2. Compute row means and variances of the matrix TBn , to yield estimates
of the means, E[Tn(m)], and variances, V ar[Tn(m)], of the test statistics
under the true data generating distribution P . That is, compute
E[TBn (m, ·)] ≡
1
B
B∑
b=1
TBn (m, b)
and V ar[TBn (m, ·)] ≡
1
B
B∑
b=1
(TBn (m, b)− E[TBn (m, ·)])2.
3. Obtain an M × B matrix, ZBn =
(
ZBn (m, b)
)
, of null value shifted and
scaled bootstrap statistics ZBn (m, b), by row-shifting and scaling the ma-
trix TBn using the bootstrap estimates of E[Tn(m)] and V ar[Tn(m)] and
the user-supplied null values λ0(m) and τ0(m). That is,
ZBn (m, b) ≡
√
min
(
1,
τ0(m)
V ar[TBn (m, ·)]
)(
TBn (m, b)−E[TBn (m, ·)]
)
+λ0(m).
(26)
For t-statistics deﬁned as in Equation (21), the null values are λ0(m) = 0
and τ0(m) = 1.
4. Estimate the null distribution Q0 by the empirical distribution Q0n of
the B columns of matrix ZBn .
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5. Compute the maximum statistic, maxm ZBn (m, b), b = 1, . . . , B, for each
bootstrap dataset, i.e., each column of the matrix ZBn .
6. For controlling the FWER at nominal level α ∈ [0, 1], the bootstrap
single-step maxT common cut-oﬀ c(Q0n, α) is deﬁned as the (1 − α)–
quantile of the empirical distribution of the B maxima {maxm ZBn (m, b) :
b = 1, . . . , B}, that is,
c(Q0n, α) ≡ inf
{
z :
1
B
B∑
b=1
I
(
max
m
ZBn (m, b) ≤ z
)
≥ (1− α)
}
. (27)
7. The bootstrap single-step maxT adjusted p-value p˜0n(m) for null hypoth-
esis H0(m) is the proportion of maxima {maxm ZBn (m, b) : b = 1, . . . , B}
that exceed the corresponding observed test statistic tn(m), that is,
p˜0n(m) =
1
B
B∑
b=1
I
(
max
m
ZBn (m, b) ≥ tn(m)
)
, m = 1, . . . ,M. (28)
4 The Gene Ontology
4.1 Overview of the Gene Ontology
The Gene Ontology (GO) Consortium (www.geneontology.org) provides on-
tologies, i.e., structured and controlled vocabularies, to describe gene prod-
ucts in terms of their associated biological processes, cellular components, and
molecular functions. The ontologies specify terminologies and relationships
among terms. They are organism-independent and can be applied even as
our knowledge of the roles of genes and proteins is accumulating and chang-
ing. The GO Consortium and other organizations supply mappings between
GO terms and genes in various organisms. Detailed documentation is available
in the “Gene Ontology Documentation” webpage (www.geneontology.org/GO.
contents.doc.html).
4.1.1 The three gene ontologies: BP, CC, and MF
The GO Consortium provides three ontologies, each consisting of a structured
network of terms describing gene products.
• Biological Process (BP or P). The Biological Process ontology refers to se-
ries of biological events that are accomplished by one or more ordered as-
semblies of molecular functions. Examples of broad BP terms are cellular
physiological process (GO:0050875) and signal transduction (GO:0007165);
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examples of more speciﬁc BP terms are pyrimidine base metabolism (GO:0006206)
and alpha-glucoside transport (GO:0000017).
• Cellular Component (CC or C). The Cellular Component ontology refers
to subcellular structures, with the proviso that the components be part
of some larger object, which may be an anatomical structure (e.g., rough
endoplasmic reticulum (GO:0005791), nucleus (GO:0005634)) or a gene
product group (e.g., ribosome (GO:0005840)).
• Molecular Function (MF or F). The Molecular Function ontology refers
to tasks or activities performed by individual (or assembled complexes
of) gene products. Examples of broad MF terms are catalytic activity
(GO:0003824), transporter activity (GO:0005215), and binding (GO:0005488);
examples of narrower MF terms are adenylate cyclase activity (GO:0004016)
and Toll binding (GO:0005121).
A gene product may be used in one or more biological processes, may be
associated with one or more cellular components, and may have one or more
molecular functions.
Example: Gene product ABL1 HUMAN. The Homo sapiens gene product
Splice Isoform IA of Proto-oncogene tyrosine-protein kinase ABL1 (ABL1 HUMAN)
can be described by the following terms in each of the three gene ontolo-
gies (AmiGO browser; Last updated 2006-02-14; www.godatabase.org/cgi-bin/
amigo/go.cgi?view=details&search_constraint=gp&session_id=6973b1139030258&gp=
P00519).
• Biological Process: regulation of progression through cell cycle (GO:0000074);
S-phase-speciﬁc transcription in mitotic cell cycle (GO:0000115); mis-
match repair (GO:0006298); regulation of transcription, DNA-dependent
(GO:0006355); DNA damage response, signal transduction resulting in
induction of apoptosis (GO:0008630).
• Cellular Component: nucleus (GO:0005634).
• Molecular Function: DNA binding (GO:0003677); protein-tyrosine kinase
activity (GO:0004713); protein binding (GO:0005515).
4.1.2 GO directed acyclic graphs
For each of the three gene ontologies, GO terms are organized in a directed
acyclic graph (DAG), where a directed graph has one-way edges and an acyclic
graph has no path starting and ending at the same vertex. Each GO term is
associated with a single vertex, or node, in the DAG. The words term, node,
and vertex, may therefore be used interchangeably.
For a given GO term, an ancestor refers to a less specialized term; an oﬀ-
spring refers to a more specialized term. A parent is an immediate/direct ances-
tor of a term; a child is an immediate/direct oﬀspring of a term. A root node has
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no parents, i.e., no incoming edges; a leaf node has no children, i.e., no outgoing
edges. In a DAG, a child may have several parents.
Every GO term must obey the so-called true path rule: if a (child) term de-
scribes a gene product, then all its immediate parent and more distant ancestor
terms must also apply to the gene product.
The DAG structure of GO terms and corresponding true path rule are ger-
mane to the deﬁnition of a suitable association measure between gene-annotation
proﬁles and gene-parameter proﬁles (Section 3.3). Furthermore, as discussed in
Sections 4.2 – 4.5, in the context of Bioconductor annotation software, the true
path rule is also relevant when assembling gene-annotation matrices.
4.1.3 GO software tools
Many software tools have been developed to deal with GO annotation metadata.
The“Gene Ontology Tools”webpage (www.geneontology.org/GO.tools.shtml)
provides a list of consortium and non-consortium software for searching and
browsing the three gene ontologies, for annotating genes and gene products
using GO, and for combined GO and gene expression microarray data analysis.
For instance, the AmiGO browser (www.godatabase.org) allows: searching for
a GO term and viewing all gene products annotated with this term; searching for
a gene product and viewing all its associated GO terms; browsing the ontologies
to view relationships among terms and gene products annotated with a given
term.
The QuickGO browser (www.ebi.ac.uk/ego), developed by the European
Bioinformatics Institute (EBI), also permits searches and graphical displays of
the Gene Ontology by GO term, GO term identiﬁer (ID), gene product, and
other identiﬁers.
Software packages developed as part of the Bioconductor Project are dis-
cussed in Sections 4.2 – 4.5.
Example: GO term protein-tyrosine kinase activity. To get a sense of the
information provided by the GO Consortium, consider the Molecular Function
ontology and the GO term protein-tyrosine kinase activity, with GO term ID
GO:0004713.
Go to the AmiGO browser (www.godatabase.org), enter the GO term ID
GO:0004713 in the Search GO box, select Exact Match, select Terms, and click
on the Submit Query button. There are two main options for displaying in-
formation on a GO term: a “tree view” and a “graphical view”. Click on the
small tree-like icon (top-left corner of the table) to display the tree view with
all ancestors (i.e., less speciﬁc terms) of the GO term protein-tyrosine kinase
activity. Click on the Graphical View button to display the portion of the MF
DAG corresponding to the GO term. Additional information may be obtained
by clicking on the hyperlinked text protein-tyrosine kinase activity.
The GO term protein-tyrosine kinase activity has one (immediate) parent,
protein kinase activity (GO:0004672), which itself has two parents, kinase ac-
tivity (GO:0016301) and phosphotransferase activity, alcohol group as acceptor
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(GO:0016773). Altogether, the term protein-tyrosine kinase activity has 7 an-
cestors. According to the true path rule, any gene annotated with the GO
term protein-tyrosine kinase activity should also be annotated with all of its
less speciﬁc ancestor terms.
The portion of the MF DAG for the GO term protein-tyrosine kinase activity
is displayed in Figures 2 and 3 using, respectively, the AmiGO and QuickGO
browsers (note the diﬀerent ordering of nodes in these two representations: for
AmiGO, the oﬀspring nodes are at the top of the graph, while for QuickGO, they
are at the bottom of the graph).
4.1.4 GO gene-annotation matrices
For each of the three gene ontologies, one may deﬁne a G ×M binary gene-
annotation matrix A, indicating for each gene g whether it is annotated or not
with each GO term m,
A(g,m) ≡
{
1, if gene g is annotated with GO term m
0, otherwise
, (29)
g = 1, . . . , G, m = 1, . . . ,M.
Section 4.5 provides sample R code for assembling GO gene-annotation ma-
trices using Bioconductor annotation metadata packages.
As detailed in Section 3, detecting associations between GO annotation and
other interesting features of a genome may be viewed as the multiple tests of the
null hypotheses of no association between a gene-parameter proﬁle λ = Λ(P ) and
gene-annotation proﬁles A(·,m). The multiple testing methodology proposed in
Dudoit and van der Laan (2006) and related articles is well-suited to handle
the complex and unknown dependence structure among test statistics implied
by the DAG structure of GO terms. The methods are illustrated in Section
5, for tests of association between diﬀerential gene expression in ALL and GO
annotation.
4.2 Overview of R and Bioconductor software for GO an-
notation metadata analysis
As discussed in Gentleman et al. (2005), the Bioconductor Project (www.bioconductor.
org) provides R packages for accessing and performing statistical inference with
GO annotation metadata. The packages include: a general annotation soft-
ware package (annotate); packages for graph theoretical analyses (e.g., graph,
Rgraphviz); a GO-speciﬁc metadata package for navigating the three GO DAGs
(GO); an Entrez Gene1-speciﬁc metadata package, providing bi-directional map-
pings between Entrez Gene IDs and GO term IDs (humanLLMappings; www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene); various Aﬀymetrix chip-speciﬁc
1N.B. The LocusLink database has been superseded by the Entrez Gene database.
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metadata packages, providing bi-directional mappings between Aﬀymetrix probe2
IDs and GO term IDs (e.g., hu6800, hgu95av2; www.affymetrix.com); a package
for annotating and generating HTML reports for Aﬀymetrix chip data (annaﬀy).
Bioconductor metadata packages are updated regularly to reﬂect the evolv-
ing nature of biological annotation metadata; it is therefore crucial to keep
track of version numbers. For information on Bioconductor software, please
consult the “Documentation” (www.bioconductor.org/docs) and “Workshops”
(www.bioconductor.org/workshops) sections of the Bioconductor Project web-
site, in addition to the standard R help facilities (e.g., help function, manuals,
etc.).
In order to run through the examples below, one needs to install and load
the following Bioconductor packages: annotate, GO, hgu95av2. The annotation
metadata used in the examples correspond to the following package versions.
> library(annotate)
> library(GO)
> library(hgu95av2)
>
> packageDescription("annotate")$Version
[1] "1.8.0"
> packageDescription("GO")$Version
[1] "1.10.0"
> packageDescription("hgu95av2")$Version
[1] "1.10.0"
Accessing and analyzing annotation metadata from databases such as Gen-
Bank (www.ncbi.nlm.nih.gov/Genbank), GO (www.geneontology.org), and
PubMed (www.pubmed.gov), presupposes the ability to perform the following
essential bookkeeping task: mapping between diﬀerent identiﬁers (ID) for a
given gene/probe. Bioconductor annotation metadata packages consist of en-
vironment objects that provide key-value mappings between diﬀerent sets of
gene/probe identiﬁers.
For instance, in the hgu95av2 annotation metadata package, for the Aﬀymetrix
chip series HG-U95Av2, the hgu95av2PMID environment provides mappings
from Aﬀymetrix probe IDs (keys) to PubMed IDs (values); similarly, the hgu95av2GO
environment provides mappings from Aﬀymetrix probe IDs (keys) to GO term
IDs (values).
Example: Aﬀymetrix probe ID 1635_at. As of Version 1.10.0 of the
hgu95av2 package, the Aﬀymetrix probe with ID 1635_at corresponds to the
gene with symbol ABL1 and long name v-abl Abelson murine leukemia vi-
ral oncogene homolog 1, located on the long arm of chromosome 9. This
probe maps to one GenBank accession number, one Entrez Gene ID, 14 distinct
GO term IDs, and 160 distinct PubMed IDs.
2N.B. In the context of Aﬀymetrix oligonucleotide chips, we use the shorter term probe
to refer to a probe-pair-set, i.e., a collection of perfect match (PM) and mismatch (MM)
probe-pairs that map to a particular gene.
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> probe <- "1635_at"
> get(probe, env=hgu95av2SYMBOL)
[1] "ABL1"
> get(probe, env=hgu95av2GENENAME)
[1] "v-abl Abelson murine leukemia viral oncogene homolog 1"
> get(probe, env=hgu95av2MAP)
[1] "9q34.1"
> get(probe, env=hgu95av2ACCNUM)
[1] "U07563"
> get(probe, env=hgu95av2LOCUSID )
[1] 25
> unique(names(get(probe, env=hgu95av2GO)))
[1] "GO:0000074" "GO:0000115" "GO:0000166" "GO:0003677" "GO:0004713"
[6] "GO:0005515" "GO:0005524" "GO:0005634" "GO:0006298" "GO:0006355"
[11] "GO:0006468" "GO:0007242" "GO:0008630" "GO:0016740"
> length(get(probe, env=hgu95av2PMID))
[1] 160
The remainder of this section gives a brief overview of two main types of
Bioconductor annotation metadata packages: the GO package (Section 4.3) and
the hgu95av2 package for the Aﬀymetrix chip series HG-U95Av2 (Section 4.4).
Section 4.5 illustrates how these two packages may be used to assemble a GO
gene-annotation matrix.
4.3 The GO annotation metadata package
The GO package provides environment objects containing key-value pairs for
mappings between GO term IDs, GO terms, GO term ancestors, GO term
parents, GO term children, GO term oﬀspring, and Entrez Gene IDs. The GO()
command lists all environments available in the GO package.
> GO()
Quality control information for GO
Date built: Created: Fri Sep 30 03:02:24 2005
Mappings found for non-probe based rda files:
GOALLLOCUSID found 9556
GOBPANCESTOR found 9888
GOBPCHILDREN found 4989
GOBPOFFSPRING found 4989
GOBPPARENTS found 9888
GOCCANCESTOR found 1612
GOCCCHILDREN found 578
GOCCOFFSPRING found 578
GOCCPARENTS found 1612
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GOLOCUSID2GO found 70818
GOLOCUSID found 8017
GOMFANCESTOR found 7334
GOMFCHILDREN found 1403
GOMFOFFSPRING found 1403
GOMFPARENTS found 7334
GOOBSOLETE found 1032
GOTERM found 18834
For information on any of the GO environments, use the help function,
e.g., help(GOTERM) or ? GOBPPARENTS. For instance, the environment GOTERM
provides mappings from GO term IDs (keys) to GO terms (values); the environ-
ments GOBPPARENTS, GOCCPARENTS, and GOMFPARENTS, provide ontology-speciﬁc
mappings from GO term IDs (keys) to GO term parent IDs (values). The en-
vironments GOALLLOCUSID, GOLOCUSID2GO, and GOLOCUSID, provide mappings
between GO term IDs and Entrez Gene IDs and are used in Section 4.5, below,
to assemble an Entrez Gene ID-by-GO term ID gene-annotation matrix for the
MF gene ontology.
Example: GO term ID GO:0004713. Let us use the GO package to obtain in-
formation on (all) ancestors, the (immediate) parents, the (immediate) children,
and (all) oﬀspring of the term corresponding to the GO term ID GO:0004713.
> ## List all GO IDs
> GOID <- ls(env = GOTERM)
> length(GOID)
[1] 18834
> GOID[1:10]
[1] "GO:0000001" "GO:0000002" "GO:0000003" "GO:0000004" "GO:0000006"
[6] "GO:0000007" "GO:0000009" "GO:0000010" "GO:0000011" "GO:0000012"
>
> ## Get information on GO term corresponding to GO ID GO:0004713
> GOID <- "GO:0004713"
> term <- get(GOID,env=GOTERM)
> class(term)
[1] "GOTerms"
attr(,"package")
[1] "annotate"
> slotNames(term)
[1] "GOID" "Term" "Synonym" "Secondary" "Definition"
[6] "Ontology"
> term
GOID = GO:0004713
Term = protein-tyrosine kinase activity
Synonym = protein tyrosine kinase activity
Definition = Catalysis of the reaction: ATP + a protein tyrosine = ADP
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+ protein tyrosine phosphate.
Ontology = MF
>
> ## Get GO IDs of parents
> parents <- get(GOID,env=GOMFPARENTS)
> parents
isa
"GO:0004672"
> mget(parents,env=GOTERM)
$"GO:0004672"
GOID = GO:0004672
Term = protein kinase activity
Definition = Catalysis of the transfer of a phosphate group, usually
from ATP, to a protein substrate.
Ontology = MF
>
> ## Get GO IDs of ancestors
> ancestors <- get(GOID,env=GOMFANCESTOR)
> ancestors
[1] "all" "GO:0003674" "GO:0003824" "GO:0016740" "GO:0016772"
[6] "GO:0016773" "GO:0016301" "GO:0004672"
>
> ## Get GO IDs of children
> children <- get(GOID,env=GOMFCHILDREN)
> children
[1] "GO:0004714" "GO:0004715" "GO:0004716"
>
> ## Get GO IDs of offspring
> offspring <- get(GOID,env=GOMFOFFSPRING)
> offspring
[1] "GO:0004714" "GO:0004715" "GO:0004716" "GO:0005020" "GO:0005021"
[6] "GO:0005023" "GO:0005010" "GO:0005011" "GO:0005017" "GO:0005003"
[11] "GO:0005006" "GO:0005007" "GO:0005008" "GO:0005009" "GO:0008288"
[16] "GO:0005018" "GO:0005019" "GO:0005004" "GO:0005005" "GO:0008313"
[21] "GO:0004718"
As already noted in the example on p. 23 and Figures 2 and 3, the term
corresponding to the GO term ID GO:0004713 is protein-tyrosine kinase activity,
in the Molecular Function ontology. It has one (immediate) parent term, protein
kinase activity.
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4.4 Aﬀymetrix chip-speciﬁc annotation metadata pack-
ages: The hgu95av2 package
The Bioconductor Project provides Aﬀymetrix chip-speciﬁc annotation meta-
data packages for the main chip series for the human, mouse, rat, and other
genomes, e.g., HU-6800, HG-U133, HG-U95, MG-U74, and RG-U34 series.
These packages, built using the infrastructure package AnnBuilder, contain en-
vironment objects for mappings between Aﬀymetrix probe IDs and other types
of gene/probe identiﬁers.
Note that analogous packages are not supplied for two-color spotted microar-
rays, as there is no standard microarray design for this type of platform and
specialized annotation metadata packages may have to be created for each mi-
croarray facility (e.g., using AnnBuilder). Once annotation metadata packages
are available to provide mappings between diﬀerent sets of gene/probe identi-
ﬁers, the tools in annotate and related packages may be used in a similar manner
for any type of microarray platform.
Consider the hgu95av2 package, for the Aﬀymetrix chip series HG-U95Av2.
This package provides the following environments.
> ? hgu95av2
> hgu95av2()
Quality control information for hgu95av2
Date built: Created: Tue Oct 4 21:31:35 2005
Number of probes: 12625
Probe number missmatch: None
Probe missmatch: None
Mappings found for probe based rda files:
hgu95av2ACCNUM found 12625 of 12625
hgu95av2CHRLOC found 11673 of 12625
hgu95av2CHR found 12145 of 12625
hgu95av2ENZYME found 1886 of 12625
hgu95av2GENENAME found 11418 of 12625
hgu95av2GO found 9942 of 12625
hgu95av2LOCUSID found 12203 of 12625
hgu95av2MAP found 12109 of 12625
hgu95av2OMIM found 9881 of 12625
hgu95av2PATH found 3928 of 12625
hgu95av2PMID found 12086 of 12625
hgu95av2REFSEQ found 12008 of 12625
hgu95av2SUMFUNC found 0 of 12625
hgu95av2SYMBOL found 12159 of 12625
hgu95av2UNIGENE found 12118 of 12625
Mappings found for non-probe based rda files:
hgu95av2CHRLENGTHS found 25
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hgu95av2ENZYME2PROBE found 643
hgu95av2GO2ALLPROBES found 5480
hgu95av2GO2PROBE found 3890
hgu95av2ORGANISM found 1
hgu95av2PATH2PROBE found 155
hgu95av2PFAM found 10439
hgu95av2PMID2PROBE found 98214
hgu95av2PROSITE found 8249
For more information on any of these environments, use the help function,
e.g., help(hgu95av2GO) or ? hgu95av2GO. We focus on the three environments
related to GO: hgu95av2GO, hgu95av2GO2ALLPROBES, and hgu95av2GO2PROBE.
The HG-U95Av2 chip contains 12,625 probes (keys in the hgu95av2GO environ-
ment), with the ﬁrst 10 Aﬀymetrix probe IDs listed below.
> ## List all Affymetrix IDs
> AffyID <- ls(env = hgu95av2GO)
> length(AffyID)
[1] 12625
> AffyID[1:10]
[1] "1000_at" "1001_at" "1002_f_at" "1003_s_at" "1004_at" "1005_at"
[7] "1006_at" "1007_s_at" "1008_f_at" "1009_at"
4.4.1 Probes-to-most speciﬁc GO terms mappings: The hgu95av2GO
environment
The hgu95av2GO environment contains key-value pairs for the mappings from
Aﬀymetrix probe IDs (keys) to GO term IDs (values). Each Aﬀymetrix probe
ID is mapped to a list of one or more elements, where each element corresponds
to a particular GO term and is itself a list of the following three elements.
• "GOID": A GO term ID corresponding to the Aﬀymetrix probe ID (key).
• "Evidence": A code for the evidence supporting the association of the
GO term to the Aﬀymetrix probe.
• "Ontology": An abbreviation for the name of the ontology to which the
GO term belongs: BP (Biological Process), CC (Cellular Component), or
MF (Molecular Function).
Note that only the directly associated terms or most speciﬁc terms (i.e., not
their less speciﬁc ancestor terms) a probe is annotated with are returned as val-
ues in hgu95av2GO. The GO package (Section 4.3) may be used to obtain more
information on the GO term IDs, e.g., GO term, (all) ancestors, (immediate)
parents, (immediate) children, and (all) oﬀspring.
Example: GO terms directly associated with Aﬀymetrix probe ID
1635_at. Let us obtain GO annotation information for the probe with Aﬀymetrix
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ID 1635_at, corresponding to the ABL1 gene. The code below shows that probe
1635_at is directly annotated with 14 distinct GO terms (the same GO term
ID may be returned multiple times with a diﬀerent evidence code). As already
noted in the example on p. 22, one of these terms, with GO term ID GO:0004713,
is protein-tyrosine kinase activity, in the Molecular Function ontology.
> probe <- "1635_at"
> probe2GO <- get(probe, env = hgu95av2GO)
> length(probe2GO)
[1] 14
> unique(names(probe2GO))
[1] "GO:0000074" "GO:0000115" "GO:0000166" "GO:0003677" "GO:0004713"
[6] "GO:0005515" "GO:0005524" "GO:0005634" "GO:0006298" "GO:0006355"
[11] "GO:0006468" "GO:0007242" "GO:0008630" "GO:0016740"
> probe2GO[[5]]
$GOID
[1] "GO:0004713"
$Evidence
[1] "TAS"
$Ontology
[1] "MF"
> get(probe2GO[[5]]$GOID, env=GOTERM)
GOID = GO:0004713
Term = protein-tyrosine kinase activity
Synonym = protein tyrosine kinase activity
Definition = Catalysis of the reaction: ATP + a protein tyrosine = ADP
+ protein tyrosine phosphate.
Ontology = MF
The hgu95av2GO environment (and analogous environments for other chip
series) may be used to assemble an Aﬀymetrix probe ID-by-GO term ID gene-
annotation matrix, row by row. This may entail, however, a number of data
processing steps. Firstly, only the most speciﬁc terms a probe is annotated
with are returned as values in hgu95av2GO. One therefore needs to add all an-
cestor (less speciﬁc) terms in order to comply with the true path rule. Sec-
ondly, several probes may correspond to the same gene, i.e., several Aﬀymetrix
probe IDs may map to the same Entrez Gene ID according to the environment
hgu95av2LOCUSID. Thirdly, the hgu95av2GO environment returns GO terms for
all three gene ontologies at once. One may need to separate terms according to
membership in the BP, CC, and MF ontologies (e.g., using the GOTERM environ-
ment from the GO package).
Alternately, one may assemble an Aﬀymetrix probe ID-by-GO term ID gene-
annotation matrix, column by column, using the hgu95av2GO2ALLPROBES envi-
ronment described below.
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4.4.2 GO terms-to-directly annotated probes mappings: The hgu95av2GO2PROBE
environment
The hgu95av2GO2PROBE environment provides key-value pairs for the mappings
from GO term IDs (keys) to Aﬀymetrix probe IDs (values). Values are vectors
of length one or greater depending on whether a given GO term ID is mapped
to one or more Aﬀymetrix probe IDs. The value names are evidence codes for
the GO term IDs.
Note that the probes a particular GO term is mapped to are only those as-
sociated directly with the GO term (vs. indirectly via its immediate children or
more distant oﬀspring). For a list of all probes associated directly or indirectly
with a particular GO term, one may use the hgu95av2GO2ALLPROBES environ-
ment.
Example: Aﬀymetrix probes directly associated with GO term ID
GO:0004713. In the following example, 205 distinct Aﬀymetrix probe IDs are as-
sociated directly with the GO term protein-tyrosine kinase activity (GO:0004713).
The Aﬀymetrix probe IDs include 1635_at, corresponding to the ABL1 gene.
> GOID <- "GO:0004713"
> GO2Probes <- get(GOID, env = hgu95av2GO2PROBE)
> length(unique(GO2Probes))
[1] 205
> GO2Probes[1:10]
<NA> <NA> <NA> <NA> <NA> TAS
"1635_at" "1636_g_at" "1656_s_at" "2040_s_at" "2041_i_at" "39730_at"
IEA IEA IEA TAS
"1084_at" "35162_s_at" "1564_at" "854_at"
> is.element("1635_at", GO2Probes)
[1] TRUE
4.4.3 GO terms-to-all annotated probes mappings: The hgu95av2GO2ALLPROBES
environment
The hgu95av2GO2ALLPROBES environment provides key-value pairs for the map-
pings from GO term IDs (keys) to Aﬀymetrix probe IDs (values). Values are
vectors of length one or greater depending on whether a given GO term ID is
mapped to one or more Aﬀymetrix probe IDs. The value names are evidence
codes for the GO term IDs.
Note that, in accordance with the true path rule, the probes a particular
GO term is mapped to are associated either directly with the GO term or in-
directly via any of its immediate children or more distant oﬀspring. The main
diﬀerence between the hgu95av2GO2PROBE and hgu95av2GO2ALLPROBES envi-
ronments is that the former considers only the GO term itself, while the later
considers the GO term and any of its descendants. Thus, the Aﬀymetrix probe
IDs returned by hgu95av2GO2PROBE are a subset of the probe IDs returned by
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hgu95av2GO2ALLPROBES.
Example: Aﬀymetrix probes directly or indirectly associated with
GO term ID GO:0004713. In the following example, 319 distinct Aﬀymetrix
probe IDs (some with multiple evidence codes) are associated either directly or
indirectly with the GO term ID GO:0004713. This list of 319 Aﬀymetrix probe
IDs indeed includes the list of 205 probe IDs associated directly with the term
GO:0004713.
> GOID <- "GO:0004713"
> GO2AllProbes <- get(GOID, env = hgu95av2GO2ALLPROBES)
> length(GO2AllProbes)
[1] 370
> length(unique(GO2AllProbes))
[1] 319
> sum(is.element(GO2Probes,GO2AllProbes))
[1] 205
The hgu95av2GO2ALLPROBES environment immediately yields an Aﬀymetrix
probe ID-by-GO term ID gene-annotation matrix, column by column. How-
ever, as with the hgu95av2GO environment, a number of data processing steps
may be required, concerning, for example, uniqueness of Entrez Gene IDs and
membership in the BP, CC, and MF ontologies.
4.5 Assembling a GO gene-annotation matrix
This section provides R code for assembling an Entrez Gene ID-by-GO term
ID gene-annotation matrix A, column by column. Speciﬁcally, rows correspond
to (unique) Entrez Gene IDs mapping to probes on the HG-U95Av2 chip and
columns to terms in the Molecular Function ontology that map directly or in-
directly to at least 10 Entrez Gene IDs for the HG-U95Av2 chip.
In practice, it may not be desirable to build the full G×M gene-annotation
matrix, as this matrix could potentially be very large and sparse (padded with
zeros). Rather, we assemble a (smaller) gene-annotation list, that provides, for
each GO term ID, a list of Entrez Gene IDs annotated with the GO term.
> ## List all Affymetrix IDs for HG-U95Av2 chip
> AffyID <- ls(env=hgu95av2GO)
> length(AffyID)
[1] 12625
>
> ## Get all unique Entrez Gene IDs for HG-U95Av2 chip
> LLID <- as.character(unique(unlist(mget(AffyID, env=hgu95av2LOCUSID))))
> length(LLID)
[1] 9085
>
> ## Get MF GO IDs
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> GOID <- ls(env=GOTERM)
> O <- unlist(lapply(mget(GOID, env=GOTERM), function(z) z@Ontology))
> table(O)
O
BP CC MF
9888 1612 7334
> MFID <- GOID[O=="MF"]
>
> ## For each MF GO ID, get all Entrez Gene IDs for genes annotated directly or indirectly w
> allMFLLID <- mget(MFID, env=GOALLLOCUSID)
>
> ## For each MF GO ID, get HG-U95Av2-specific Entrez Gene IDs for genes annotated directly
> MFLLID <- lapply(allMFLLID, function(z) intersect(z, LLID))
> numMFLLID <- unlist(lapply(MFLLID, length))
> summary(numMFLLID)
Min. 1st Qu. Median Mean 3rd Qu. Max.
0.000 1.000 1.000 9.539 1.000 6762.000
>
> ## Retain only MF GO IDs that map to at least 10 Entrez Gene IDs for the HG-U95Av2 chip
> MFAnnotList <- MFLLID[numMFLLID > 9]
> length(MFAnnotList)
[1] 466
> summary(unlist(lapply(MFAnnotList, length)))
Min. 1st Qu. Median Mean 3rd Qu. Max.
10.0 16.0 27.5 132.2 70.0 6762.0
> MFAnnotList[1]
$"GO:0000146"
[1] "4620" "4621" "4624" "4625" "4640" "4643" "4644" "4646" "4647"
[10] "4650" "58498"
>
> ## Get Affymetrix IDs for probes annotated with GO term ID GO:0004713
> is.element("GO:0004713",names(MFAnnotList))
[1] TRUE
> length(MFAnnotList["GO:0004713"][[1]])
[1] 180
5 Tests of association between GO annotation
and diﬀerential gene expression in ALL
5.1 Acute lymphoblastic leukemia dataset of Chiaretti et
al. (2004)
Our proposed approach to tests of association with biological annotation meta-
data is illustrated using the acute lymphoblastic leukemia (ALL) microarray
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dataset of Chiaretti et al. (2004) and Gene Ontology (GO) annotation meta-
data.
5.1.1 Bioconductor experimental data R package ALL
The ALL dataset is available in the Bioconductor experimental data R package
ALL (Version 1.0.2, Bioconductor Release 1.7). The main object in this package
is ALL, an instance of the class exprSet. The exprs slot of ALL provides a matrix
of 12,625 Aﬀymetrix expression measures (chip series HG-U95Av2) for each of
128 ALL cell samples. The phenoData slot contains 21 phenotypes, i.e., responses
and covariates, for each of the 128 cell samples. Phenotypes of interest include:
ALL$BT, the type and stage of the cancer, i.e., B-cell ALL or T-cell ALL, of stage
1, 2, 3, or 4; ALL$mol.biol, the molecular class of the cancer, i.e., BCR/ABL,
NEG, ALL1/AF4, E2A/PBX1, p15/p16, or NUP-98.
The expression measures have been obtained using the three-step robust
multichip average (RMA) pre-processing method, implemented in the Biocon-
ductor R package aﬀy (Bolstad et al., 2005), and have been subjected to a base
2 logarithmic transformation. For greater detail on the ALL dataset, please
consult the ALL package documentation.
5.1.2 The BCR/ABL fusion
A number of recent articles have investigated the prognostic relevance of the
BCR/ABL fusion in adult ALL of the B-cell lineage (Gleissner et al., 2002).
The BCR/ABL fusion is the molecular analogue of the Philadelphia chromo-
some, one of the most frequent cytogenetic abnormalities in human leukemias.
This t(9;22) translocation leads to a head-to-tail fusion of the v-abl Abel-
son murine leukemia viral oncogene homolog 1 (ABL1) from chromosome
9 with the 5’ half of the breakpoint cluster region (BCR) on chromosome
22 (Figure 4). The ABL1 proto-oncogene encodes a cytoplasmic and nuclear
protein tyrosine kinase that has been implicated in processes of cell diﬀerentia-
tion, cell division, cell adhesion, and stress response. Although the BCR/ABL
fusion protein, encoded by sequences from both the ABL1 and BCR genes, has
been extensively studied, the function of the normal product of the BCR gene is
not clear. The BCR/ABL proto-oncogene has been found to be highly-expressed
in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) cells
(Mukhopadhyay et al., 2002).
An interesting question is therefore the identiﬁcation of genes that are dif-
ferentially expressed between B-cell ALL with the BCR/ABL fusion and cyto-
genetically normal NEG B-cell ALL.
In order to address this quesion, we consider the expression measures of the
n = 79 B-cell ALL cell samples (ALL$BT equal to B, B1, B2, B3, or B4), of the
BCR/ABL or NEG molecular types (ALL$mol.biol equal to BCR/ABL or NEG).
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5.1.3 Gene ﬁltering
Many of the genes represented by the 12,625 probes are not expressed in B-cell
lymphocytes. Accordingly, as in von Heydebreck et al. (2004), we only retain
the 2,391 probes that meet the following two criteria: (i) ﬂuorescence intensities
greater than 100 (absolute scale) for at least 25% of the 79 cell samples; (ii)
interquartile range (IQR) of the ﬂuorescence intensities for the 79 cell samples
greater than 0.5 (log base 2 scale).
Furthermore, diﬀerent probes may correspond to the same gene, i.e., map to
the same Entrez Gene ID, according to the environment hgu95av2LOCUSID from
the hgu95av2 package. In order to obtain one expression measure per gene, we
choose to average the expression measures of multiple probes mapping to the
same gene.
These various pre-processing steps lead to G = 2, 071 genes with unique
Entrez Gene IDs.
5.1.4 Reduced ALL dataset: Genotypes and phenotypes of interest
The combined genotypic and phenotypic data for the n = 79 B-cell ALL cell
samples of the BCR/ABL and NEG molecular types may be summarized by
the set XYn ≡ {(Xi, Yi) : i = 1, . . . , n}, of n pairs of G–dimensional gene
expression proﬁles Xi = (Xi(g) : g = 1, . . . , G), G = 2, 071, and cancer class
labels Yi ∈ {NEG,BCR/ABL}. Among the n = 79 B-cell ALL cell samples,
there are nBCR/ABL ≡
∑
i I(Yi = BCR/ABL) = 37 BCR/ABL and nNEG ≡∑
i I(Yi = NEG) = 42 NEG samples.
5.2 Multiple hypothesis testing framework
Our primary question of interest is the identiﬁcation of genes that are diﬀeren-
tially expressed (DE) between BCR/ABL and NEG B-cell ALL. A subsequent
question involves relating diﬀerential gene expression to GO annotation.
As detailed below, GO annotation metadata for the ﬁltered list of G = 2, 071
unique genes from the HG-U95Av2 chip may be summarized by binary gene-
annotation proﬁles.
The gene-parameter proﬁles of interest concern diﬀerential gene expression
between BCR/ABL and NEG B-cell ALL, i.e., the association between microar-
ray gene expression measures and cancer class. Continuous gene-parameter pro-
ﬁles of unstandardized and standardized measures of diﬀerential expression are
estimated, respectively, by (unstandardized) diﬀerences of empirical means and
(standardized) two-sample t-statistics. Binary gene-parameter proﬁles, indicat-
ing whether genes are diﬀerentially expressed or not, are estimated by imposing
cut-oﬀ rules on two-sample t-statistics or adjusted p-values.
The following association measures between GO gene-annotation proﬁles
and DE gene-parameter proﬁles are considered: two-sample t-statistics for tests
of association between binary GO gene-annotation proﬁles and continuous DE
gene-parameter proﬁles; χ2-statistics for tests of association between binary GO
gene-annotation proﬁles and binary DE gene-parameter proﬁles.
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Signiﬁcant associations between diﬀerential gene expression and GO anno-
tation are identiﬁed by applying FWER-controlling bootstrap-based single-step
maxT Procedure 2.
5.2.1 Gene-annotation proﬁles
Gene Ontology annotation metadata for the HG-U95Av2 chip series are ob-
tained as described in Sections 4.2 – 4.5, from the following Bioconductor R
packages: the GO-speciﬁc metadata package GO (Version 1.10.0, Bioconduc-
tor Release 1.7) and the Aﬀymetrix chip-speciﬁc metadata package hgu95av2
(Version 1.10.0, Bioconductor Release 1.7).
For each of the three gene ontologies, binary gene-annotation matrices ABP ,
ACC , and AMF , are assembled for the GO terms annotating at least 10 of the
G = 2, 071 ﬁltered genes (sample R code provided in Section 4.5). Speciﬁcally,
for gene ontology o ∈ {BP,CC,MF}, Ao = (Ao(g,m) : g = 1, . . . , G; m =
1, . . . ,Mo) is a G×Mo matrix, with element Ao(g,m) indicating whether gene
g is annotated or not by GO term m and such that
∑
g Ao(g,m) ≥ 10 for each
term m. The numbers of terms considered in each gene ontology are MBP = 367,
MCC = 81, and MMF = 185.
5.2.2 Gene-parameter proﬁles
Deﬁnition of gene-parameter proﬁles Consider a data structure (X,Y ) ∼
P , where X = (X(g) : g = 1, . . . , G) is a G = 2, 071–dimensional vector
of microarray gene expression measures and Y ∈ {NEG,BCR/ABL} is a
cancer class label. Let πk ≡ Pr(Y = k) denote the proportion of cancers
of class k ∈ {NEG,BCR/ABL}. Deﬁne conditional G–dimensional mean
vectors and G × G covariance matrices for the expression measures of class
k ∈ {NEG,BCR/ABL} cancers by
µk ≡ E[X|Y = k] and σk ≡ Cov[X|Y = k],
respectively.
Gene-parameter proﬁles, concerning diﬀerential gene expression between BCR/ABL
and NEG B-cell ALL, may be speciﬁed in various ways. Continuous DE gene-
parameter proﬁles may be deﬁned in terms of the following unstandardized and
standardized measures of diﬀerential gene expression between BCR/ABL and
NEG B-cell ALL,
λd(g) ≡ µBCR/ABL(g)− µNEG(g) (30)
and λt(g) ≡ µBCR/ABL(g)− µNEG(g)√
σBCR/ABL(g,g)
πBCR/ABL
+ σNEG(g,g)πNEG
.
Absolute values of λd(g) and λt(g) may be used for measuring two-sided diﬀer-
ential expression, i.e., either over- or under-expression in BCR/ABL compared
to NEG B-cell ALL.
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Binary DE gene-parameter proﬁles may be deﬁned in terms of indicators for
two-sided and one-sided diﬀerential expression.
λ =(g) ≡ I(µBCR/ABL(g) = µNEG(g)) = I(λd(g) = 0) = I(λt(g) = 0),(31)
λ+(g) ≡ I(µBCR/ABL(g) > µNEG(g)) = I(λd(g) > 0) = I(λt(g) > 0),
and λ−(g) ≡ I(µBCR/ABL(g) < µNEG(g)) = I(λd(g) < 0) = I(λt(g) < 0).
Estimation of gene-parameter proﬁles The above DE gene-parameter
proﬁles may be estimated as follows, based on the dataset XYn of gene ex-
pression measures for the n = 79 B-cell ALL cell samples of the BCR/ABL and
NEG molecular types.
The resubstitution estimators of the continuous gene-parameter proﬁles of
Equation (30) are based, respectively, on diﬀerences of empirical means and
two-sample Welch t-statistics (up to the multiplier 1/
√
n). That is,
λdn(g) ≡ µBCR/ABL,n(g)− µNEG,n(g) (32)
and λtn(g) ≡
1√
n
µBCR/ABL,n(g)− µNEG,n(g)√
σBCR/ABL,n(g,g)
nBCR/ABL
+ σNEG,n(g,g)nNEG
,
where µk,n(g) ≡
∑
i I(Yi = k)Xi(g)/nk and σk,n(g, g) ≡
∑
i I(Yi = k)(Xi(g) −
µk,n(g))2/(nk − 1) denote, respectively, the empirical means and variances of
the gene expression measures for cancers of class k ∈ {NEG,BCR/ABL}.
Estimating the two-sided binary gene-parameter proﬁle λ = of Equation (31)
involves the two-sided tests of the G null hypotheses H0(g) = I(µBCR/ABL(g) =
µNEG(g)), of no diﬀerences in mean gene expression measures between BCR/ABL
and NEG B-cell ALL. Likewise, estimating the one-sided binary gene-parameter
proﬁles λ+ and λ− involves, respectively, the one-sided tests of the G null hy-
potheses of no over-expression (H0(g) = I(µBCR/ABL(g) ≤ µNEG(g))) and no
under-expression (H0(g) = I(µBCR/ABL(g) ≥ µNEG(g))) in BCR/ABL compared
to NEG B-cell ALL. For single-step common-cut-oﬀ maxT Procedure 1, ad-
justed p-values produce the same gene rankings as the test statistics deﬁned in
Equation (32). Simple and naive estimators of the three sets of diﬀerentially
expressed genes (i.e., true positives), represented by the gene-parameter proﬁles
λ =, λ+, and λ−, are therefore given, respectively, by the sets of genes with the
largest γG values of |λtn(g)|, λtn(g), and −λtn(g). That is,
λ =n,γG(g) ≡ I
⎛⎝ G∑
g′=1
I(|λtn(g)| ≥ |λtn(g′)|) ≥ (1− γ)G
⎞⎠ , (33)
λ+n,γG(g) ≡ I
⎛⎝ G∑
g′=1
I(λtn(g) ≥ λtn(g′)) ≥ (1− γ)G
⎞⎠ ,
and λ−n,γG(g) ≡ I
⎛⎝ G∑
g′=1
I(−λtn(g) ≥ −λtn(g′)) ≥ (1− γ)G
⎞⎠ .
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Analogous estimators may also be based on other test statistics, such as unstan-
dardized diﬀerence statistics λdn. More sophisticated estimators, that translate
the proportion γ of rejected hypotheses into a Type I error rate such as the
gFWER, TPPFP, or FDR, could be based on adjusted p-values for the multiple
tests of the G null hypotheses H0(g). For example, one could estimate λ = by
λ =n,α(g) ≡ I
(
P˜ =0n(g) ≤ α
)
, (34)
where P˜ =0n(g) are adjusted p-values for a suitably chosen multiple testing pro-
cedure, such as, FWER-controlling single-step maxT Procedure 1 or a TPPFP-
controlling augmentation multiple testing procedure (Chapter 6, Dudoit and
van der Laan (2006); van der Laan et al. (2004a)). One-sided binary gene-
parameter proﬁles λ+ and λ− could be estimated likewise.
5.2.3 Association measures for gene-annotation and gene-parameter
proﬁles
The association between continuous DE gene-parameter proﬁles, as in Equation
(30), and binary GO gene-annotation proﬁles may be measured by two-sample
Welch t-statistics (or corresponding p-values). Speciﬁcally, given a continuous
G–vector x and a binary G–vector y, deﬁne the following association measure,
ρt(x, y) ≡ x¯1 − x¯0√
v[x]1
y1
+ v[x]0y0
, (35)
where yk ≡
∑
g I(y(g) = k), x¯k ≡
∑
g I(y(g) = k)x(g)/yk, and v[x]k ≡
∑
g I(y(g) =
k)(x(g)− x¯k)2/(yk − 1), k ∈ {0, 1}.
The association between binary DE gene-parameter proﬁles, as in Equation
(31), and binary GO gene-annotation proﬁles may be measured by χ2-statistics
(or corresponding p-values) for the test of independence of rows and columns in
a 2× 2 contingency table, such as Table 2. Speciﬁcally, given binary G–vectors
x and y, deﬁne the following association measure,
ρχ(x, y) ≡ G(g00g11 − g01g10)
2
(g00 + g01)(g00 + g10)(g11 + g01)(g11 + g10)
, (36)
where gkk′ ≡
∑
g I(x(g) = k)I(y(g) = k
′), k, k′ ∈ {0, 1}.
Given an association measure3 ρ : IRG×M × IRG → IRM , a G×M GO gene-
annotation matrix A, and a G–dimensional DE gene-parameter proﬁle λ =
Λ(P ), the M–dimensional association parameter vector ψ = Ψ(P ) of primary
interest is deﬁned as
ψ ≡ ρ(A, λ). (37)
3N.B. For ease of notation, ρt and ρχ, deﬁned in Equations (35) and (36) as real-valued
association measures, may also refer loosely to IRM–valued association measures, deﬁned as
ρt(X, y) ≡ (ρt(X(·, m), y) : m = 1, . . . , M) and ρχ(X, y) ≡ (ρχ(X(·, m), y) : m = 1, . . . , M)
for X ∈ IRG×M and y ∈ IRG.
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The corresponding resubstitution estimator ψn = Ψˆ(Pn) is simply obtained by
replacing the gene-parameter proﬁle λ by an estimator thereof λn = Λˆ(Pn), that
is,
ψn ≡ ρ(A, λn). (38)
5.2.4 Null and alternative hypotheses
For the t-statistic-based association measure ρt of Equation (35), the identiﬁca-
tion of GO terms m that are signiﬁcantly (positively or negatively) associated
with BCR/ABL vs. NEG diﬀerential gene expression involves the two-sided
tests of the M null hypotheses H0(m) = I(ψ(m) = ψ0(m)) against the al-
ternative hypotheses H1(m) = I(ψ(m) = ψ0(m)), with null values ψ0(m) =
0. In some contexts, one may be interested in identifying positive (negative)
associations, i.e., in the one-sided tests of the M null hypotheses H0(m) =
I(ψ(m) ≤ ψ0(m)) (H0(m) = I(ψ(m) ≥ ψ0(m))) against the alternative hy-
potheses H1(m) = I(ψ(m) > ψ0(m)) (H1(m) = I(ψ(m) < ψ0(m))).
For the χ2-statistic-based association measure ρχ of Equation (36), the iden-
tiﬁcation of GO terms m that are signiﬁcantly (positively or negatively) associ-
ated with BCR/ABL vs. NEG diﬀerential gene expression involves the one-sided
tests of the M null hypotheses H0(m) = I(ψ(m) ≤ ψ0(m)) against the alterna-
tive hypotheses H1(m) = I(ψ(m) > ψ0(m)). A natural choice for the null values
is the mean of the χ2(1)-distribution, ψ0(m) = 1.
5.2.5 Test statistics
One-sided and two-sided tests of null hypotheses concerning any of the asso-
ciation parameters deﬁned above may be based on (unstandardized) diﬀerence
statistics Tn(m), deﬁned as in Equation (20).
For one-sided tests, large values of the test statistics Tn(m) provide evidence
against the corresponding null hypotheses H0(m), that is, rejection regions are
of the form Cn(m) = (cn(m),+∞). For two-sided tests, large values of the
absolute test statistics |Tn(m)| provide evidence against the corresponding null
hypotheses H0(m).
5.2.6 Multiple testing procedures
For the purpose of illustration, we focus on control of the family-wise error rate,
using single-step maxT Procedure 1, based on the non-parametric bootstrap
null value shifted test statistics null distribution (null shift values λ0(m) = 0
and no scaling). The main steps are outlined in Procedure 2.
Bootstrap-based single-step maxT adjusted p-values P˜0n(m) are computed
as in Equation (28). Let On(m) denote indices for the ordered adjusted p-values,
so that P˜0n(On(1)) ≤ . . . ≤ P˜0n(On(M)). GO terms with adjusted p-values less
than or equal to α are declared signiﬁcantly associated with diﬀerential gene
expression at nominal FWER level α. That is, the list of GO terms found to be
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associated with diﬀerential gene expression is
Rn(α) = {m : P˜0n(m) ≤ α} = {On(1), . . . , On(Rn(α))},
where Rn(α) ≡ |Rn(α)| denotes the number of identiﬁed GO terms.
5.2.7 Summary of testing scenarios
This section summarizes our approach for identifying GO terms associated with
BCR/ABL vs. NEG diﬀerential gene expression. For each of the three gene
ontologies (i.e., BP, CC, and MF), we consider the following three types of
testing scenarios, each corresponding to a diﬀerent association parameter ψ =
ρ(A, λ) for GO annotation and BCR/ABL vs. NEG diﬀerential gene expression.
Scenarios MT[t, t] and MT[d, t] are very similar and correspond, respectively, to
continuous gene-parameter proﬁles of standardized and unstandardized measures
of diﬀerential gene expression. In contrast, Scenario MT[=, χ] corresponds to a
binary gene-parameter proﬁle of diﬀerential gene expression indicators.
1. Scenario MT[t, t]: Association parameter ψt,t ≡ ρt(A, |λt|), for
standardized continuous DE gene-parameter proﬁle λt. Consider
the two-sided tests of
Ht,t0 (m) ≡ I(ψt,t(m) = ψt,t0 (m)) vs. Ht,t1 (m) ≡ I(ψt,t(m) = ψt,t0 (m)),
where the association parameter vector of interest is deﬁned as ψt,t ≡
ρt(A, |λt|), based on Equations (30) and (35), and the null values are
ψt,t0 (m) ≡ 0. The continuous DE gene-parameter proﬁle λt is estimated by
λtn, as in Equation (32), and the association parameter ψ
t,t is estimated
by the resubstitution estimator ψt,tn ≡ ρt(A, |λtn|), as in Equation (38).
The test statistics are deﬁned as (unstandardized) diﬀerence statistics,
T t,tn (m) ≡
√
n(ψt,tn (m)− ψt,t0 (m)),
and the null hypotheses Ht,t0 (m) are rejected for large absolute values of
T t,tn (m).
2. Scenario MT[d, t]: Association parameter ψd,t ≡ ρt(A, |λd|), for un-
standardized continuous DE gene-parameter proﬁle λd. Consider
the two-sided tests of
Hd,t0 (m) ≡ I(ψd,t(m) = ψd,t0 (m)) vs. Hd,t1 (m) ≡ I(ψd,t(m) = ψd,t0 (m)),
where the association parameter vector of interest is deﬁned as ψd,t ≡
ρt(A, |λd|), based on Equations (30) and (35), and the null values are
ψd,t0 (m) ≡ 0. The continuous DE gene-parameter proﬁle λd is estimated
by λdn, as in Equation (32), and the association parameter ψ
d,t is estimated
by the resubstitution estimator ψd,tn ≡ ρt(A, |λdn|), as in Equation (38).
The test statistics are deﬁned as (unstandardized) diﬀerence statistics,
T d,tn (m) ≡
√
n(ψd,tn (m)− ψd,t0 (m)),
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and the null hypotheses Hd,t0 (m) are rejected for large absolute values of
T d,tn (m).
3. Scenario MT[ =, χ]: Association parameter ψ =,χ ≡ ρχ(A, λ =), for
binary DE gene-parameter proﬁle λ =. Consider the one-sided tests
of
H =,χ0 (m) ≡ I(ψ =,χ(m) ≤ ψ =,χ0 (m)) vs. H =,χ1 (m) ≡ I(ψ =,χ(m) > ψ =,χ0 (m)),
where the association parameter vector of interest is deﬁned as ψ =,χ ≡
ρχ(A, λ =), based on Equations (31) and (36), and the null values are
ψ =,χ0 (m) ≡ 1 (the mean of the χ2(1)-distribution). The following two
types of estimators λ =n are considered for the binary DE gene-parameter
proﬁle λ =: λ =n,γG, with numbers of DE genes γG = 20, 50, 100 (Equation
(33)); λ =n,α, deﬁned in terms of adjusted p-values for FWER-controlling
permutation-based single-step maxT Procedure 1 (B = 1, 000 permuta-
tions of the cancer class labels) and nominal level α = 0.05 (Equation
(34)). Given an estimator λ =n of λ
=, the association parameter ψ =,χ is
estimated by the resubstitution estimator ψ =,χn ≡ ρχ(A, λ =n ), as in Equa-
tion (38). The test statistics are deﬁned as (unstandardized) diﬀerence
statistics,
T =,χn (m) ≡
√
n(ψ =,χn (m)− ψ =,χ0 (m)),
and the null hypotheses H =,χ0 (m) are rejected for large values of T
=,χ
n (m).
For each of the three testing scenarios, the test statistics null value shifted
null distribution Q0 is estimated as in Procedure 2, with B = 5, 000 non-
parametric bootstrap samples of the data XYn and ZBn (m, b) = TBn (m, b) −
E[TBn (m, ·)] (i.e., null shift values λ0(m) = 0 and no scaling). Bootstrap-
based single-step maxT adjusted p-values P˜0n(m) are computed as in Equation
(28) for one-sided testing Scenario MT[=, χ]. For two-sided testing Scenarios
MT[t, t] and MT[d, t], adjusted p-values are computed based on absolute values
of ZBn (m, b) and Tn(m).
In what follows, the G–dimensional gene-parameter proﬁles λ correspond
to the G = 2, 071 genes with unique Entrez Gene IDs, obtained as described
in Section 5.1. For each of the three gene ontologies, binary gene-annotation
matrices are assembled for the GO terms annotating at least 10 of the G = 2, 071
genes of interest: G = 2, 071×MBP = 367 gene-annotation matrix ABP for the
BP ontology, G = 2, 071×MCC = 81 gene-annotation matrix ACC for the CC
ontology, and G = 2, 071 ×MMF = 185 gene-annotation matrix AMF for the
MF ontology.
5.3 Results
5.3.1 Diﬀerentially expressed genes between BCR/ABL and NEG
B-cell ALL
In order to identify diﬀerentially expressed genes between BCR/ABL and NEG
B-cell ALL, two-sided tests of the G null hypotheses H0(g) = I(µBCR/ABL(g) =
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µNEG(g)) are performed using the two-sample t-statistics λtn(g) of Equation (32)
and FWER-controlling bootstrap-based single-step maxT Procedure 2. Ad-
justed p-values P˜ =0n(g) are obtained using the MTP function from the multtest
package (Version 1.8.0, Bioconductor Release 1.7), with B = 5, 000 non-parametric
bootstrap samples and other arguments set to their default values.
Figure 5 displays a normal quantile-quantile plot of the test statistics λtn(g)
(Panel (a)) and a plot of the sorted bootstrap-based single-step maxT adjusted
p-values P˜ =0n(g) (Panel (b)). A handful of genes stand out in terms of their large
absolute test statistics and small adjusted p-values.
For control of the FWER at nominal level α = 0.05, Procedure 2 identiﬁes
16 diﬀerentially expressed genes, i.e., 16 genes with P˜ =0n(g) ≤ α. Table 3 pro-
vides the test statistics, adjusted p-values, and various identiﬁers for these 16
genes. A more detailed hyperlinked table is posted on the website companion
(Supplementary Table 1; www.stat.berkeley.edu/~sandrine/Docs/Papers/
DFF06/DFF.html).
Only two of the 16 identiﬁed genes have a negative test statistic (MX1 and
TPD52L2), suggesting that most DE genes tend to be over-expressed in cell sam-
ples with the BCR/ABL fusion. The gene showing the most over-expression in
BCR/ABL cell samples, as measured by the t-statistics λtn, is the ABL1 gene (v-
abl Abelson murine leukemia viral oncogene homolog 1), located on the
long arm of chromosome 9 (9q34.1). As mentioned in Section 5.1, the BCR/ABL
phenotype is indeed deﬁned in terms of the ABL1 gene.
Furthermore, many of the DE genes seem to be related to apoptosis or
oncogenesis. For example, the Kruppel-like factor 9 (KLF9) gene encodes
a transcription factor that binds GC-box elements in gene promoter regions.
The Kru¨ppel-like factor (KLF) family is comprised of highly-related zinc-ﬁnger
proteins, that are important components of the eukaryotic cellular transcrip-
tional machinery and that take part in a wide range of cellular functions (e.g.,
cell proliferation, apoptosis, diﬀerentiation, and neoplastic transformation). In
particular, KLFs have been linked to various cancers (Kaczynski et al., 2003).
The intron-less gene AHNAK nucleoprotein (desmoyokin) (AHNAK), located on
the long arm of chromosome 11 (11q12.2), encodes an unusually large protein
(≈ 700kDa) that is typically repressed in cell lines derived from human neu-
roblastomas and several other types of tumors (Shtivelman et al., 1992). Yet
another example, the caspase 8, apoptosis-related cysteine peptidase
(CASP8) gene, encodes a key enzyme at the top of the apoptotic cascade and has
been linked to neuroblastoma (Banelli et al., 2002). Likewise, other genes listed
in Table 3, including MX1, FYN, ACTN1, FHL1, and TRAM2, appear to be related
to the molecular biology of cancer. For further detail, the interested reader is
invited to consult Supplementary Table 1 and follow links to PubMed and other
databases.
Our results are in general agreement with those of von Heydebreck et al.
(2004), slight diﬀerences being due, most likely, to our preliminary gene ﬁltering,
which involves averaging the expression measures of multiple probes mapping
to the same Entrez Gene ID.
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5.3.2 GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL
Figure 6 displays, for each of the three gene ontologies and each of the three
testing scenarios, plots of the sorted adjusted p-values, P˜0n(On(1)) ≤ . . . ≤
P˜0n(On(M)), for FWER-controlling bootstrap-based single-step maxT Proce-
dure 2 (B = 5, 000 bootstrap samples). The smaller the adjusted p-values, the
less conservative the procedure and the longer the list Rn(α) = {m : P˜0n(m) ≤
α} of identiﬁed GO terms at any given nominal Type I error level α. Table 4
summarizes the results in terms of the numbers Rn(α) = |Rn(α)| of GO terms
found to be signiﬁcantly associated with BCR/ABL vs. NEG diﬀerential gene
expression at diﬀerent nominal FWER levels α.
In general, adjusted p-values tend to be quite large, with only a handful
of GO terms identiﬁed as being signiﬁcantly associated with BCR/ABL vs.
NEG diﬀerential gene expression at nominal FWER level α ∈ {0.05, 0.10, 0.20}.
The adjusted p-values for Scenarios MT[t, t] and MT[d, t] (red and blue plot-
ting symbols), corresponding, respectively, to standardized and unstandardized
continuous DE gene-parameter proﬁles, are similar: for the BP and MF gene on-
tologies, Scenario MT[t, t] seems to be slightly more conservative than Scenario
MT[d, t], however, this does not hold for the CC ontology. Scenario MT[=, χ],
with four diﬀerent estimators of the binary DE gene-parameter proﬁle λ =, tends
to be more conservative than either Scenario MT[t, t] or MT[d, t]. Furthermore,
the choice of parameter γG, for the number of genes called diﬀerentially ex-
pressed, can have a substantial impact on the adjusted p-values for Scenario
MT[=, χ : γG]. There are some indications, especially for the CC ontology,
that larger values of the parameter γG lead to larger numbers of identiﬁed GO
terms. Note that for Scenario MT[=, χ], the p-value-based estimator λ =n,α, with
α = 0.05, and the naive estimator λ =n,γG, with γG = 20, yield very similar results
(green and purple plotting symbols). Indeed, when applied to the entire dataset
of n = 79 cell samples, permutation-based single-step maxT Procedure 1 iden-
tiﬁes 20 genes as being diﬀerentially expressed between BCR/ABL and NEG
B-cell ALL at nominal FWER level α = 0.05. In other words, λ =n,0.05 and λ
=
n,20
yield the same estimate of the binary gene-parameter proﬁle λ = for the set of DE
genes. Minor discrepancies between the results of Scenarios MT[=, χ : α = 0.05]
and MT[=, χ : γG = 20] are due to the fact that while the estimators λ =n,0.05
and λ =n,20 coincide on the full dataset, they may diﬀer on bootstrap samples of
these data.
Next, the three testing scenarios are compared in terms of the contents of the
lists Rn(α) of identiﬁed GO terms. Speciﬁcally, let On(r) ≡ {On(1), . . . , On(r)}
denote the set of indices corresponding to the r smallest adjusted p-values for
a given gene ontology and testing scenario. Measures of agreement between
testing scenarios are provided by the numbers of common GO terms among
sets of ordered GO terms On(r) of various cardinality r, i.e., by the cardinality
of the intersections between sets On(r) for diﬀerent testing scenarios. Figure
7 displays plots of numbers of common GO terms for pairs of testing scenar-
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ios. As expected, there is substantial overlap between the GO terms identiﬁed
by Scenarios MT[t, t] and MT[d, t] for continuous DE gene-parameter proﬁles
(blue plotting symbols in top panels). This suggests that, for the ALL dataset,
standardized (λt) and unstandardized (λd) continuous measures of diﬀerential
gene expression have similar properties. In contrast, there is much less overlap
between the GO terms identiﬁed by Scenario MT[=, χ], for binary DE gene-
parameter proﬁles, and either Scenario MT[t, t] or MT[d, t]. For example, for the
MF gene ontology, among the top 10 GO terms On(10) identiﬁed by each testing
scenario, 6 are common to Scenarios MT[t, t] and MT[d, t], whereas at most 3
are common to Scenarios MT[t, t] and MT[=, χ]. Again, note the near perfect
agreement between Scenarios MT[=, χ : α = 0.05] and MT[=, χ : γG = 20]
(purple plotting symbols in lower panels). Figure 7 again illustrates the lack of
robustness of Scenario MT[=, χ : γG] to the choice of parameter γG.
Moreover, examine graphical summaries of the joint distributions of the es-
timated continuous DE gene-parameter proﬁle λtn and the gene-annotation pro-
ﬁles A(·,m) for the top two GO terms m ∈ {On(1), On(2)} identiﬁed according
to each testing scenario. Figure 8 displays conditional boxplots of λtn given
A(·,m), that is, boxplots of the unannotated and annotated estimated gene-
parameter proﬁles, (λtn(g) : A(g,m) = 0) and (λ
t
n(g) : A(g,m) = 1), respec-
tively. While the boxplots reveal clear diﬀerences (non-overlapping notches)
between unannotated and annotated proﬁles for some of the GO terms (e.g.,
MF term GO:0003735), the diﬀerences can be subtle for other terms (e.g., MF
term GO:0003924). Not surprisingly, the most extreme diﬀerences are seen
with Scenarios MT[t, t] and MT[d, t], and, to a lesser extent, with Scenario
MT[=, χ : α = 0.05] for the CC ontology. The boxplots again illustrate dif-
ferences between Scenario MT[=, χ] and either Scenario MT[t, t] or MT[d, t].
Tables 5, 6, and 7 report various p-value-based measures of association be-
tween the estimated DE gene-parameter proﬁles λtn and λ
=
n,α and the gene-
annotation proﬁles A(·,m) for the top two GO terms m ∈ {On(1), On(2)} iden-
tiﬁed according to each testing scenario, in the BP, CC, and MF gene ontologies,
respectively. The transformation to the [0, 1] p-value scale allows a more direct
comparison of the various testing scenarios. The tables again highlight the dif-
ferences between Scenario MT[=, χ], for binary DE gene-parameter proﬁles, and
either Scenario MT[t, t] or MT[d, t], for continuous DE gene-parameter proﬁles.
As expected, Scenarios MT[t, t] and MT[d, t] tend to identify GO terms with
small p-values P t,t0n (m) for t-tests of association between estimated continuous
gene-parameter proﬁles λtn and gene-annotation proﬁles A(·,m). In contrast,
and also as expected, Scenario MT[=, χ] tends to identify GO terms with small
p-values P =,χ0n (m) for χ
2-tests of association between estimated binary gene-
parameter proﬁles λ =n,α and gene-annotation proﬁles A(·,m). Furthermore, the
tables corroborate our earlier observation that Scenario MT[=, χ] tends to be
more conservative than either Scenario MT[t, t] or MT[d, t]. Indeed, some of the
GO terms with small p-values P t,t0n (m) for continuous gene-parameter proﬁles
have very large p-values P =,χ0n (m) for binary gene-parameter proﬁles (e.g., MF
term GO:0003735 in Table 7). Such terms are likely to be identiﬁed by Sce-
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narios MT[t, t] and MT[d, t], but “missed” by Scenario MT[=, χ]. The converse
phenomenon is not as striking. However, one should keep in mind that Scenario
MT[=, χ] depends on the choice of estimator for the binary DE gene-parameter
proﬁle λ =, i.e., on parameters such as α and γG. In particular, with certain val-
ues of α (or γG), binary Scenario MT[=, χ] may become more similar to either
continuous Scenario MT[t, t] or MT[d, t]. Column A1(m) in Tables 5, 6, and 7
suggests that, compared to Scenario MT[=, χ], Scenarios MT[t, t] and MT[d, t]
tend to identify GO terms annotating a larger number of genes (this observation
also holds for the top 20 terms identiﬁed according to each testing scenario; data
not shown).
Figure 9 displays a scatterplot matrix of the 50 smallest adjusted p-values,
based on Scenario MT[t, t], for each of the three gene ontologies. The plots
indicate that more terms tend to be identiﬁed in the BP ontology compared to
either the CC or MF ontologies, and fewer terms tend to be identiﬁed in the MF
ontology compared to either the BP or CC ontologies. Note that comparisons
based on adjusted p-values take into account diﬀerences in the numbers of tested
hypotheses, MBP = 367, MCC = 81, and MMF = 185, for each ontology.
Tables 8, 9, and 10 list the 20 GO terms with the smallest adjusted p-values
for Scenario MT[t, t], applied to the BP, CC, and MF gene ontologies, respec-
tively. Figures 10, 11, and 12 display portions of the directed acyclic graphs
for the top 20 GO terms in each ontology. The ﬁgures suggest that GO terms
associated with BCR/ABL vs. NEG diﬀerential gene expression tend to concen-
trate in certain branches of the DAGs, i.e., diﬀerential expression is associated
with related properties of gene products. While it is known that many of the
eﬀects of the BCR/ABL fusion are mediated by tyrosine kinase activity, the
MF GO term protein-tyrosine kinase activity (GO:0004713) does not appear to
be signiﬁcantly associated with diﬀerential gene expression between BCR/ABL
and NEG B-cell ALL (adjusted p-value of 0.8890 for Scenario MT[t, t]).
For illustration purposes, we further investigate two of the GO terms from
Tables 8 and 10: GO term anti-apoptosis (GO:0006916), with ninth smallest
adjusted p-value for Scenario MT[t, t] applied to the BP gene ontology, and GO
term structural constituent of ribosome (GO:0003735), with the smallest ad-
justed p-value for Scenario MT[t, t] applied to the MF gene ontology. Tables 11
and 12 list genes directly or indirectly annotated with GO terms GO:0006916
and GO:0003735, respectively. Figure 13 displays mean-diﬀerence plots of the
average expression measures in BCR/ABL and NEG cell samples for genes an-
notated with GO terms GO:0006916 and GO:0003735.
Panel (a) in Figure 13 indicates that genes annotated with BP GO term
anti-apoptosis (GO:0006916) tend to be over-expressed in BCR/ABL compared
to NEG cell samples. Among these 21 genes, only SOCS2 is signiﬁcantly diﬀeren-
tially expressed between BCR/ABL and NEG B-cell ALL (nominal FWER level
α = 0.05, Table 3). However, a brief survey of the literature reveals that several
of the genes in Table 11 interact with the BCR/ABL proto-oncogene. For in-
stance, Kirchner et al. (2003) investigate mechanisms for the BCR/ABL-mediated
activation of the transcription factor NF-κB/Rel encoded by the NFKB1 gene.
Their ﬁndings suggest that NF-κB/Rel may be a potential target for molecular
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therapies of leukemia. Mukhopadhyay et al. (2002) demonstrate that ectopic
expression of BCR/ABL interferes with the tumor necrosis factor (TNF) sig-
naling pathway through the down-regulation of TNF receptors. The TNF gene
encodes a multifunctional proinﬂammatory cytokine involved in the regulation
of a wide spectrum of biological processes, including cell proliferation, diﬀeren-
tiation, apoptosis, lipid metabolism, and coagulation. The TNF gene has been
implicated in a variety of diseases, including autoimmune diseases, insulin resis-
tance, and cancer.
As seen in Table 12, 22 of the 24 genes annotated with MF GO term struc-
tural constituent of ribosome (GO:0003735) code for ribosomal proteins. Al-
though none of the 24 annotated genes are identiﬁed as being signiﬁcantly dif-
ferentially expressed between BCR/ABL and NEG B-cell ALL (nominal FWER
level α = 0.05, Table 3), Panel (b) in Figure 13 suggests that these genes tend
to be under-expressed in BCR/ABL cell samples.
6 Discussion
We have proposed a general and formal statistical framework for multiple tests
of association with biological annotation metadata. A key component of our ap-
proach is the systematic and precise translation of a generic biological question
into a corresponding multiple hypothesis testing problem, concerning association
measures between known gene-annotation proﬁles and unknown gene-parameter
proﬁles. This general and rigorous formulation of the statistical inference ques-
tion allows us to apply the multiple testing methodology developed in Dudoit
and van der Laan (2006) and related articles, to control a broad class of Type I
error rates, in testing problems involving general data generating distributions
(with arbitrary dependence structures among variables), null hypotheses, and
test statistics.
The ﬂexibility of our approach was illustrated using the ALL microarray
dataset of Chiaretti et al. (2004), with the aim of relating GO annotation to dif-
ferential gene expression between BCR/ABL and NEG B-cell ALL. This analysis
demonstrates the importance of selecting a suitable DE gene-parameter proﬁle λ
and measure ρ for the association between this gene-parameter proﬁle and GO
gene-annotation proﬁles A. Indeed, for the ALL dataset, the choice of gene-
parameter proﬁle for measuring diﬀerential expression between BCR/ABL and
NEG B-cell ALL had a large impact on the list of identiﬁed GO terms. Test-
ing scenarios based on binary DE gene-parameter proﬁles (Scenario MT[=, χ])
tended to be more conservative than scenarios based on continuous DE gene-
parameter proﬁles (Scenarios MT[t, t] and MT[d, t]), with little overlap between
the lists of identiﬁed GO terms. Furthermore, testing scenarios based on binary
gene-parameter proﬁles were sensitive to the somewhat arbitrary DE/non-DE
gene dichotomization, that is, Scenario MT[=, χ : γG] lacked robustness with
respect to the choice of parameter γG for the number of genes called diﬀer-
entially expressed according to the estimator λ =n,γG. In contrast, continuous
gene-parameter proﬁles based on standardized and unstandardized measures of
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diﬀerential gene expression lead to very similar results (Scenarios MT[t, t] and
MT[d, t]).
Our results on the ALL microarray dataset clearly show the limitations of
binary gene-parameter proﬁles of diﬀerential expression indicators, which are
still the norm for combined GO annotation and microarray data analyses. Our
proposed statistical framework, with general deﬁnitions for the gene-annotation
and gene-parameter proﬁles, allows consideration of a much broader class of
inference problems, that extend beyond GO annotation and microarray data
analysis. Gene-annotation proﬁles may be continuous or polychotomous and
may correspond, for example, to intron/exon counts/lengths/nucleotide distri-
butions, gene pathway membership, or gene regulation by particular transcrip-
tion factors. Likewise, gene-parameter proﬁles may be continuous or polychoto-
mous and may correspond, for example, to regression coeﬃcients relating possi-
bly censored biological and clinical outcomes to genome-wide transcript levels,
DNA copy numbers, and other covariates.
This ﬁrst application of our proposed methodology only considered control
of the family-wise error rate using single-step common-cut-oﬀ maxT Procedure
1, based on the non-parametric bootstrap null value shifted test statistics null
distribution. Adjusted p-values tended to be quite large, with only a hand-
ful of GO terms identiﬁed as being signiﬁcantly associated with BCR/ABL
vs. NEG diﬀerential gene expression. Joint stepwise augmentation and em-
pirical Bayes procedures could be used for control of a broader and more bi-
ologically relevant class of Type I error rates, deﬁned as tail probabilities,
gTP (q, g) = Pr(g(Vn, Rn) > q), for arbitrary functions g(Vn, Rn) of the num-
bers of false positives Vn and rejected hypotheses Rn (Dudoit and van der Laan,
2006; Dudoit et al., 2004a; van der Laan et al., 2004a,b, 2005). Error rates based
on the proportion Vn/Rn of false positives (e.g., TPPFP and FDR) are espe-
cially appealing for large-scale testing problems, compared to error rates based
on the number Vn of false positives (e.g., gFWER), as they do not increase
exponentially with the number M of tested hypotheses. More powerful analy-
ses may also be achieved with the new null quantile-transformed test statistics
null distribution of van der Laan and Hubbard (2005). The multiple testing
methodology developed in Dudoit and van der Laan (2006) and related articles
is particularly well-suited to handle the variety of parameters of interest and
the complex and unknown dependence structures among test statistics (e.g.,
implied by the DAG structure of GO terms) that are likely to be encountered in
these and other high-dimensional inference problems in biomedical and genomic
research.
Ongoing eﬀorts include consideration of more general and biologically per-
tinent multivariate association measures ρ. For instance, for GO annotation
metadata, the association parameter for a given GO term could take into ac-
count the structure of the DAG by considering the gene-annotation proﬁles of
oﬀspring or ancestor terms. We are also interested in developing better numeri-
cal and graphical methods for representing and interpreting the multiple testing
results, e.g., the lists of GO terms and associated adjusted p-values. Finally,
we are planning on implementing the proposed methods in an R package to be
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released as part of the Bioconductor Project.
Software and website companion
The multiple testing procedures proposed in Dudoit and van der Laan (2006)
and related articles (Birkner et al., 2005; Dudoit et al., 2004a,b; Keles¸ et al.,
2004; van der Laan et al., 2004a,b, 2005; van der Laan and Hubbard, 2005;
Pollard et al., 2005a,b; Pollard and van der Laan, 2004; Rubin et al., 2005)
are implemented in the R package multtest, released as part of the Bioconduc-
tor Project, an open-source software project for the analysis of biomedical and
genomic data (Pollard et al. (2005b); www.bioconductor.org).
The experimental data (ALL) and annotation metadata (annaﬀy, annotate,
GO, hgu95av2) packages used in the analysis of Section 5 may also be obtained
from the Bioconductor Project website.
The website companion to this article provides additional tables, ﬁgures,
code, and references: www.stat.berkeley.edu/~sandrine/Docs/Papers/DFF06/
DFF.html.
Acknowledgment
We are most grateful to Robert Gentleman for many stimulating discussions on
statistical and computational methods for the analysis of biological annotation
metadata.
49
Hosted by The Berkeley Electronic Press
Table 1: Type I and Type II errors in multiple hypothesis testing. This table sum-
marizes the diﬀerent types of decisions and errors in multiple hypothesis testing.
The number of rejected hypotheses is Rn ≡ |Rn| =
∑M
m=1 I(Tn(m) ∈ Cn(m)),
the number of Type I errors is Vn ≡ |Rn∩H0| =
∑
m∈H0 I(Tn(m) ∈ Cn(m)), and
the number of Type II errors is Un ≡ |Rcn ∩H1| =
∑
m∈H1 I(Tn(m) /∈ Cn(m)).
Null hypotheses
non-rejected rejected
true |Rcn ∩H0| Vn = |Rn ∩H0| h0 = |H0|
(Type I)
Null hypotheses
false Un = |Rcn ∩H1| |Rn ∩H1| h1 = |H1|
(Type II)
M −Rn Rn = |Rn| M
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Table 2: Association parameters for binary gene-annotation proﬁles and gene-
parameter proﬁles. Given a binary gene-annotation proﬁle A(·,m) and a binary
gene-parameter proﬁle λ, one may build a 2 × 2 contingency table, with rows
corresponding to the gene-annotation proﬁle and columns to the gene-parameter
proﬁle. Cell counts are deﬁned as gkk′(m) ≡
∑
g I(A(g,m) = k)I(λ(g) = k
′),
k, k′ ∈ {0, 1}. For instance, g11(m) corresponds to the number of genes scored
as one for both the gene-annotation proﬁle and the gene-parameter proﬁle, i.e.,
the number of genes possessing both features of interest.
Gene-parameter proﬁle, λ
1 0
Gene- 1 g11(m) = g10(m) = A1(m) =
annotation
PG
g=1 A(g,m)λ(g)
PG
g=1 A(g,m)(1 − λ(g))
PG
g=1 A(g,m)
proﬁle,
A(·,m) 0 g01(m) = g00(m) = A0(m) =PG
g=1(1 − A(g,m))λ(g)
PG
g=1(1 − A(g,m))(1 − λ(g))
PG
g=1(1 − A(g,m))
Gλ¯ =
PG
g=1 λ(g) G(1 − λ¯) =
PG
g=1(1 − λ(g)) G
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Table 3: Diﬀerentially expressed genes between BCR/ABL and
NEG B-cell ALL. This table provides the Aﬀymetrix probe IDs,
Entrez Gene IDs (hgu95av2LOCUSID environment in hgu95av2
package), gene symbols (hgu95av2SYMBOL environment), gene
names (hgu95av2GENENAME environment), test statistics λtn(g)
(Equation (32)), and adjusted p-values P˜ =0n(g) (Equation (28)) for
the 16 genes found to be signiﬁcantly diﬀerentially expressed be-
tween BCR/ABL and NEG B-cell ALL, at nominal FWER level
α = 0.05, according to bootstrap-based single-step maxT Proce-
dure 2, with two-sample t-statistics λtn(g) and B = 5, 000 bootstrap
samples. A more detailed hyperlinked table, including information
on gene function, chromosomal location, links to GenBank, Entrez
Gene, NCBI Map Viewer, UniGene, PubMed, AmiGO, and KEGG,
is provided on the website companion (Supplementary Table 1).
Probe ID Entrez Gene ID Symbol λtn(g) P˜
=
0n(g)
1635_at 25 ABL1 8.44 0
v-abl Abelson murine leukemia viral oncogene homolog 1
40202_at 687 KLF9 6.33 0
Kruppel-like factor 9
37027_at 79026 AHNAK 5.71 0.0014
AHNAK nucleoprotein (desmoyokin)
39837_s_at 168544 ZNF467 5.45 0.0034
zinc finger protein 467
33774_at 841 CASP8 5.29 0.0042
caspase 8, apoptosis-related cysteine peptidase
37014_at 4599 MX1 -5.23 0.0050
myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
2039_s_at 2534 FYN 5.21 0.0050
FYN oncogene related to SRC, FGR, YES
39329_at 87 ACTN1 4.97 0.0096
actinin, alpha 1
32542_at 2273 FHL1 4.96 0.0102
four and a half LIM domains 1
40051_at 9697 TRAM2 4.59 0.0268
translocation associated membrane protein 2
38032_at 9900 SV2A 4.54 0.0308
synaptic vesicle glycoprotein 2A
39319_at 3937 LCP2 4.50 0.0346
lymphocyte cytosolic protein 2
(SH2 domain containing leukocyte protein of 76kDa)
33232_at 1396 CRIP1 4.46 0.0368
cysteine-rich protein 1 (intestinal)
Continued on next page ...
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... continued from previous page
Probe ID Entrez Gene ID Symbol λtn(g) P˜
=
0n(g)
36591_at 7277 TUBA1 4.37 0.0444
tubulin, alpha 1 (testis specific)
38994_at 8835 SOCS2 4.35 0.0466
suppressor of cytokine signaling 2
40076_at 7165 TPD52L2 -4.33 0.0480
tumor protein D52-like 2
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Table 4: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL. This table reports, for each of the three gene
ontologies and each of the three testing scenarios, the numbers Rn(α) = |Rn(α)|
of GO terms found to be signiﬁcantly associated with BCR/ABL vs. NEG dif-
ferential gene expression at diﬀerent nominal FWER levels α.
Nominal FWER level, α
0.05 0.10 0.20 0.05 0.10 0.20 0.05 0.10 0.20
MT[t, t] 2 6 14 3 4 5 1 1 3
MT[d, t] 1 5 16 3 5 7 1 2 4
MT[ =, χ : α = 0.05] 0 3 5 0 0 0 1 1 1
MT[ =, χ : γG = 20] 0 0 0 0 0 0 1 1 1
MT[ =, χ : γG = 50] 0 0 1 2 2 2 0 0 0
MT[ =, χ : γG = 100] 0 0 2 1 1 2 0 0 0
BP CC MF
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Table 5: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, top two BP GO terms. This table provides
association measures between the estimated DE gene-parameter proﬁles λtn and
λ =n,α and the gene-annotation proﬁles A(·,m) for the top two BP GO terms
m ∈ {On(1), On(2)} identiﬁed according to each of the three testing scenarios.
A1(m) ≡
∑
g A(g,m): Number of genes directly or indirectly annotated with
GO term m (out of G = 2, 071 genes, GOALLLOCUSID environment in GO pack-
age). P t,t0n (m): Nominal unadjusted p-value for the two-sample t-test comparing
the unannotated and annotated estimated continuous DE gene-parameter pro-
ﬁles, (λtn(g) : A(g,m) = 0) and (λ
t
n(g) : A(g,m) = 1), respectively (t.test
function from the R stats package, with default argument values). P =,χ0n (m):
Unadjusted p-value for the χ2-test of independence between the estimated bi-
nary DE gene-parameter proﬁle λ =n,α, α = 0.05, and the gene-annotation proﬁle
A(·,m) (chisq.test function from the R stats package, with arguments simu-
late.p.value = TRUE, correct=FALSE). P˜0n(m): Bootstrap-based single-step
maxT adjusted p-value, according to which the top two GO terms are identiﬁed
for each testing scenario.
BP
Scenario GO term A1(m) P
t,t
0n (m) P
=,χ
0n (m) P˜0n(m)
MT[t, t] GO:0008152 1076 0 0.1704 0.0262
GO:0044237 1045 0 0.1824 0.0428
MT[d, t] GO:0006091 98 0 0.6172 0.0366
GO:0000226 14 0.0018 1 0.0582
MT[=, χ : α = 0.05] GO:0008361 27 0.0553 0.0035 0.0828
GO:0016049 27 0.0553 0.0010 0.0828
MT[=, χ : γG = 20] GO:0008361 27 0.0553 0.0020 0.2078
GO:0016049 27 0.0553 0.0020 0.2078
MT[=, χ : γG = 50] GO:0048522 87 0.0356 0.0120 0.1860
GO:0048518 96 0.0439 0.0145 0.2338
MT[=, χ : γG = 100] GO:0050793 24 0.0854 0.0175 0.1458
GO:0007155 59 0.0006 0.1109 0.1980
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Table 6: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, top two CC GO terms. Details in Table
5 caption.
CC
Scenario GO term A1(m) P
t,t
0n (m) P
=,χ
0n (m) P˜0n(m)
MT[t, t] GO:0005840 25 0 1 0.0056
GO:0030529 77 0 0.6387 0.0138
MT[d, t] GO:0005840 25 0 1 0.0040
GO:0005830 11 0 1 0.0052
MT[=, χ : α = 0.05] GO:0005578 10 0.0167 0.0775 0.4940
GO:0031012 10 0.0167 0.0815 0.4940
MT[=, χ : γG = 20] GO:0005578 10 0.0167 0.1069 0.3500
GO:0031012 10 0.0167 0.0975 0.3500
MT[=, χ : γG = 50] GO:0005576 54 0.0009 1 0.0078
GO:0005615 31 0.0480 0.2509 0.0078
MT[=, χ : γG = 100] GO:0005576 54 0.0009 1 0.0488
GO:0005615 31 0.0480 0.2439 0.1280
Table 7: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, top two MF GO terms. Details in Table
5 caption.
MF
Scenario GO term A1(m) P
t,t
0n (m) P
=,χ
0n (m) P˜0n(m)
MT[t, t] GO:0003735 24 0 1 0.0024
GO:0003723 143 0 0.4068 0.1168
MT[d, t] GO:0003735 24 0 1 0.0022
GO:0003723 143 0 0.3968 0.0784
MT[=, χ : α = 0.05] GO:0004930 10 0.2241 0.0065 0.0366
GO:0003924 34 0.6501 0.0395 0.7046
MT[=, χ : γG = 20] GO:0004930 10 0.2241 0.0025 0.0168
GO:0003924 34 0.6501 0.0495 0.6210
MT[=, χ : γG = 50] GO:0004930 10 0.2241 0.0040 0.4108
GO:0030246 22 0.8582 0.1919 0.4794
MT[=, χ : γG = 100] GO:0005509 69 0.0004 0.1399 0.3140
GO:0004930 10 0.2241 0.0025 0.3262
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Table 8: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, top 20 BP GO terms. This table lists the
20 GO terms with the smallest adjusted p-values for Scenario MT[t, t] applied
to the BP gene ontology. A1(m) ≡
∑
g A(g,m): Number of genes directly or
indirectly annotated with GO term m (out of G = 2, 071 genes, GOALLLOCUSID
environment in GO package). P˜0n(m): Bootstrap-based single-step maxT ad-
justed p-value for Scenario MT[t, t].
BP, Scenario MT[t, t]
GO term ID GO term A1(m) P˜0n(m)
GO:008152 metabolism 1076 0.0262
GO:044237 cellular metabolism 1045 0.0428
GO:009058 biosynthesis 187 0.0750
GO:044238 primary metabolism 1002 0.0750
GO:044249 cellular biosynthesis 169 0.0862
GO:006091 generation of precursor metabolites 98 0.0928
and energy
GO:019882 antigen presentation 15 0.1098
GO:030333 antigen processing 14 0.1444
GO:006916 anti-apoptosis 21 0.1564
GO:043066 negative regulation of apoptosis 26 0.1692
GO:043069 negative regulation of programmed 26 0.1692
cell death
GO:007154 cell communication 390 0.1754
GO:006457 protein folding 52 0.1910
GO:007165 signal transduction 351 0.1946
GO:000226 microtubule cytoskeleton organization 14 0.2302
and biogenesis
GO:006082 organic acid metabolism 65 0.2538
GO:006163 purine nucleotide metabolism 29 0.2820
GO:007155 cell adhesion 59 0.2822
GO:007028 cytoplasm organization and biogenesis 10 0.2976
GO:019752 carboxylic acid metabolism 63 0.3108
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Table 9: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, top 20 CC GO terms. Details in Table 8
caption.
CC, Scenario MT[t, t]
GO term ID GO term A1(m) P˜0n(m)
GO:0005840 ribosome 25 0.0056
GO:0030529 ribonucleoprotein complex 77 0.0138
GO:0005830 cytosolic ribosome (sensu Eukaryota) 11 0.0144
GO:0043234 protein complex 334 0.0778
GO:0005886 plasma membrane 200 0.1316
GO:0005829 cytosol 78 0.2204
GO:0005737 cytoplasm 578 0.2304
GO:0005887 integral to plasma membrane 125 0.2338
GO:0031226 intrinsic to plasma membrane 125 0.2338
GO:0019866 inner membrane 37 0.2574
GO:0005743 mitochondrial inner membrane 28 0.2636
GO:0005746 mitochondrial electron transport chain 11 0.2692
GO:0000502 proteasome complex (sensu Eukaryota) 26 0.2714
GO:0000323 lytic vacuole 28 0.2866
GO:0005764 lysosome 28 0.2866
GO:0005576 extracellular region 54 0.3130
GO:0005773 vacuole 29 0.3172
GO:0005622 intracellular 1152 0.3350
GO:0043228 non-membrane-bound organelle 218 0.3524
GO:0043232 intracellular non-membrane-bound 218 0.3524
organelle
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Table 10: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, top 20 MF GO terms. Details in Table 8
caption.
MF, Scenario MT[t, t]
GO term ID GO term A1(m) P˜0n(m)
GO:0003735 structural constituent of ribosome 24 0.0024
GO:0003723 RNA binding 143 0.1168
GO:0048037 cofactor binding 11 0.1518
GO:0051082 unfolded protein binding 47 0.2210
GO:0016853 isomerase activity 28 0.2348
GO:0016491 oxidoreductase activity 89 0.3476
GO:0005509 calcium ion binding 69 0.3496
GO:0015399 primary active transporter activity 57 0.4314
GO:0004872 receptor activity 101 0.4518
GO:0004871 signal transducer activity 242 0.4566
GO:0016765 transferase activity, transferring alkyl 10 0.4570
or aryl (other than methyl) groups
GO:0016860 intramolecular oxidoreductase activity 13 0.4636
GO:0016614 oxidoreductase activity, acting on 18 0.4734
CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on 18 0.4734
the CH-OH group of donors,
NAD or NADP as acceptor
GO:0043169 cation binding 230 0.5002
GO:0005489 electron transporter activity 47 0.5420
GO:0005386 carrier activity 73 0.5502
GO:0004888 transmembrane receptor activity 59 0.5690
GO:0003824 catalytic activity 635 0.5826
GO:0003676 nucleic acid binding 449 0.6718
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Table 11: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, BP GO term GO:0006916. This table lists
genes directly or indirectly annotated with GO term anti-apoptosis (out of
G = 2, 071 genes, GOALLLOCUSID environment in GO package). The term anti-
apoptosis (GO:0006916) has the ninth smallest adjusted p-value for Scenario
MT[t, t] applied to the BP gene ontology (Table 8).
BP GO:0006916
Probe ID Symbol Name
1237_at IER3 immediate early response 3
1295_at RELA v-rel reticuloendotheliosis viral oncogene
homolog A, nuclear factor of kappa light
polypeptide gene enhancer in B-cells 3, p65 (avian)
1377_at NFKB1 nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1 (p105)
1564_at AKT1 v-akt murine thymoma viral oncogene homolog 1
1830_s_at TGFB1 transforming growth factor, beta 1
(Camurati-Engelmann disease)
1852_at TNF tumor necrosis factor (TNF superfamily, member 2)
1997_s_at BAX BCL2-associated X protein
277_at MCL1 myeloid cell leukemia sequence 1 (BCL2-related)
31536_at RTN4 reticulon 4
32060_at BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2
33284_at MPO myeloperoxidase
36578_at BIRC2 baculoviral IAP repeat-containing 2
38578_at TNFRSF7 tumor necrosis factor receptor superfamily, member 7
38771_at HDAC1 histone deacetylase 1
38994_at SOCS2 suppressor of cytokine signaling 2
39097_at SON SON DNA binding protein
39378_at BECN1 beclin 1 (coiled-coil, myosin-like
BCL2 interacting protein)
39436_at BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like
40570_at FOXO1A forkhead box O1A (rhabdomyosarcoma)
595_at TNFAIP3 tumor necrosis factor, alpha-induced protein 3
641_at PSEN1 presenilin 1 (Alzheimer disease 3)
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Table 12: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, MF GO term GO:0003735. This table lists
genes directly or indirectly annotated with GO term structural constituent of
ribosome (out of G = 2, 071 genes, GOALLLOCUSID environment in GO package).
The term structural constituent of ribosome (GO:0003735) has the smallest ad-
justed p-value for Scenario MT[t, t] applied to the MF gene ontology (Table
10).
MF GO:0003735
Probe ID Symbol Name
2016_s_at RPL10 ribosomal protein L10
31511_at RPS9 ribosomal protein S9
31546_at RPL18 ribosomal protein L18
31955_at FAU Finkel-Biskis-Reilly murine sarcoma virus
(FBR-MuSV) ubiquitously expressed (fox derived)
32221_at MRPS18B mitochondrial ribosomal protein S18B
32315_at RPS24 ribosomal protein S24
32394_s_at RPL23 ribosomal protein L23
32433_at RPL15 ribosomal protein L15
32437_at RPS5 ribosomal protein S5
33117_r_at RPS12 ribosomal protein S12
33485_at RPL4 ribosomal protein L4
33614_at RPL18A ribosomal protein L18a
33661_at RPL5 ribosomal protein L5
33668_at RPL12 ribosomal protein L12
33674_at RPL29 ribosomal protein L29
34316_at RPS15A ribosomal protein S15a
36358_at RPL9 ribosomal protein L9
36572_r_at ARL6IP ADP-ribosylation factor-like 6
interacting protein
36786_at RPL10A ribosomal protein L10a
39856_at RPL36AL ribosomal protein L36a-like
39916_r_at RPS15 ribosomal protein S15
41152_f_at RPL36A ribosomal protein L36a
41214_at RPS4Y1 ribosomal protein S4, Y-linked 1
41746_at NHP2L1 NHP2 non-histone chromosome protein
2-like 1 (S. cerevisiae)
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A λ
Gene-annotation profiles, A
Known, fixed G x M matrix
G genes G genes
M features
Gene-parameter profile, λ
Unknown G-vector,
 to be estimated
Data: X1, X2, …, Xn ~ P
Association parameter vector
ψ = (ψ(m): m=1, …, M)
Unknown M-vector, to be estimated
ψ(m) = ρm(A,λ)
Figure 1: Association parameters for gene-annotation proﬁles and gene-
parameter proﬁles.
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Figure 2: DAG for MF GO term GO:0004713, AmiGO. Portion of the directed
acyclic graph for the GO term protein-tyrosine kinase activity (GO:0004713),
in the Molecular Function ontology. This display, obtained using the AmiGO
browser (Last updated 2006-02-14; www.godatabase.org), shows the nodes cor-
responding to all (less speciﬁc) ancestors of the term protein-tyrosine kinase
activity.
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Figure 3: DAG for MF GO term GO:0004713, QuickGO. Portion of the directed
acyclic graph for the GO term protein-tyrosine kinase activity (GO:0004713), in
the Molecular Function ontology. This display, obtained using the EBI QuickGO
browser (Last updated 2001-03-30 04:29:44.0; www.ebi.ac.uk/ego), shows the
nodes corresponding to all (less speciﬁc) ancestors of the term protein-tyrosine
kinase activity.
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Panel (a): t(9;22) translocation
Panel (b): Karyotype
Figure 4: The Philadelphia chromosome and the BCR/ABL fusion. The
BCR/ABL fusion is the molecular analogue of the Philadelphia chromosome.
This t(9;22) translocation leads to a head-to-tail fusion of the v-abl Abel-
son murine leukemia viral oncogene homolog 1 (ABL1) from chromosome
9 with the 5’ half of the breakpoint cluster region (BCR) on chromosome 22.
(Figure obtained from the Genetic Science Learning Center, The University of
Utah; gslc.genetics.utah.edu/units/disorders/karyotype/reciprocal.
cfm).
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Panel (a): Test statistics Panel (b): Adjusted p-values
Figure 5: Diﬀerentially expressed genes between BCR/ABL and NEG B-cell
ALL. Panel (a): Normal quantile-quantile plot of two-sample t-statistics λtn(g).
Panel (b): Plot of sorted bootstrap-based single-step maxT adjusted p-values
P˜ =0n(g).
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Figure 6: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, adjusted p-values. Plots of sorted bootstrap-
based single-step maxT adjusted p-values P˜0n(m), for each of the three gene
ontologies and each of the three testing scenarios.
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Figure 7: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, common terms between testing scenarios.
Plots of numbers of common GO terms among sets of ordered GO terms On(r)
of various cardinality r for pairs of testing scenarios. Scenario MT[t, t] is used as
the baseline in the top panels and Scenario MT[=, χ : α = 0.05], with adjusted
p-value-based estimator λ =n,α, α = 0.05, for the binary DE gene-parameter pro-
ﬁle λ =, is used as the baseline in the bottom panels. For example, the blue curve
in the top left panel is a plot of |Od,tn (r)∩Ot,tn (r)| vs. r for the MF gene ontology,
i.e., of the overlap between the r most signiﬁcant MF GO terms according to
Scenarios MT[d, t] and MT[t, t].
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Figure 8: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, conditional distribution of λtn given A. Con-
ditional boxplots of the estimated continuous DE gene-parameter proﬁle λtn
given the gene-annotation proﬁles A(·,m) for the top two GO terms m ∈
{On(1), On(2)} identiﬁed according to each of the three testing scenarios. Rows
correspond to gene ontologies and columns to testing scenarios. In each panel,
the white and gray boxplots correspond, respectively, to the GO terms with
the smallest and second smallest adjusted p-values; boxplots for unannotated
and annotated estimated gene-parameter proﬁles, (λtn(g) : A(g,m) = 0) and
(λtn(g) : A(g,m) = 1), are labeled as 0 and 1, respectively. Non-overlapping
notches (informally) represent large diﬀerences in medians.
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Figure 9: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, comparison of adjusted p-values for the three
gene ontologies. Scatterplot matrix of the 50 smallest adjusted p-values for each
of the three gene ontologies, based on Scenario MT[t, t]. The identity line is
drawn for reference.
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Figure 10: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, DAG for top 20 BP GO terms. Portion
of the directed acyclic graph for the 20 GO terms with the smallest adjusted
p-values for Scenario MT[t, t] applied to the BP gene ontology (AmiGO). Nodes
for the top 20 terms are shaded in turquoise.
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Figure 11: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, DAG for top 20 CC GO terms. Portion
of the directed acyclic graph for the 20 GO terms with the smallest adjusted
p-values for Scenario MT[t, t] applied to the CC gene ontology (AmiGO). Nodes
for the top 20 terms are shaded in turquoise.
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Figure 12: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, DAG for top 20 MF GO terms. Portion
of the directed acyclic graph for the 20 GO terms with the smallest adjusted
p-values for Scenario MT[t, t] applied to the MF gene ontology (AmiGO). Nodes
for the top 20 terms are shaded in turquoise.
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Figure 13: GO terms associated with diﬀerential gene expression between
BCR/ABL and NEG B-cell ALL, BP GO term GO:0006916 and MF GO term
GO:0003735. This ﬁgure displays mean-diﬀerence plots of average expression
measures in BCR/ABL and NEG cell samples, i.e., plots of µBCR/ABL,n(g) −
µNEG,n(g) vs. (µBCR/ABL,n(g) + µNEG,n(g))/2, for genes directly or indirectly
annotated with GO terms GO:0006916 (Panel (a)) and GO:0003735 (Panel (b)).
The term anti-apoptosis (GO:0006916) has the ninth smallest adjusted p-value
for Scenario MT[t, t] applied to the BP gene ontology (Tables 8 and 11) and the
term structural constituent of ribosome (GO:0003735) has the smallest adjusted
p-value for Scenario MT[t, t] applied to the MF gene ontology (Tables 10 and
12).
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